WO2003004493A1 - Novel compounds, their preparation and use - Google Patents

Novel compounds, their preparation and use Download PDF

Info

Publication number
WO2003004493A1
WO2003004493A1 PCT/DK2002/000460 DK0200460W WO03004493A1 WO 2003004493 A1 WO2003004493 A1 WO 2003004493A1 DK 0200460 W DK0200460 W DK 0200460W WO 03004493 A1 WO03004493 A1 WO 03004493A1
Authority
WO
WIPO (PCT)
Prior art keywords
benzo
dioxide
thiazolyl
formula
thiophenyl
Prior art date
Application number
PCT/DK2002/000460
Other languages
French (fr)
Other versions
WO2003004493A8 (en
Inventor
Dan Peters
Gunnar M. Olsen
Elsebet Ostergaard Nielsen
Philip K. Ahring
Tino Dyhring Jorgensen
Original Assignee
Neurosearch A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK02754549T priority Critical patent/DK1406900T3/en
Priority to EP02754549A priority patent/EP1406900B1/en
Priority to AU2002320958A priority patent/AU2002320958B2/en
Priority to CA002448913A priority patent/CA2448913A1/en
Priority to JP2003510660A priority patent/JP2004532899A/en
Priority to NZ529880A priority patent/NZ529880A/en
Application filed by Neurosearch A/S filed Critical Neurosearch A/S
Priority to DE60215172T priority patent/DE60215172T2/en
Priority to MXPA04000012A priority patent/MXPA04000012A/en
Priority to US10/482,363 priority patent/US7314870B2/en
Publication of WO2003004493A1 publication Critical patent/WO2003004493A1/en
Publication of WO2003004493A8 publication Critical patent/WO2003004493A8/en
Priority to HK05101039A priority patent/HK1068628A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Definitions

  • the present invention relates to novel compounds that are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters.
  • the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
  • CNS central nervous system
  • PNS peripheral nervous system
  • acetylcholine exert its biological effect via two types of cholinergic receptors, the muscarinic Acetyl Choline Receptors (mAChR) and the nicotinic Acetyl Choline Receptors (nAChR).
  • mAChR muscarinic Acetyl Choline Receptors
  • nAChR nicotinic Acetyl Choline Receptors
  • muscarinic acetylcholine receptors dominate quantitatively over nicotinic acetylcholine receptors in the brain area important to memory and cognition, and much research aimed at the development of agents for the treatment of memory related disorders have focused on the synthesis of muscarinic acetylcholine receptor modulators.
  • nAChR modulators have emerged.
  • diseases are associated with degeneration of the cholinergic system i.e. senile dementia of the Alzheimer type, vascular dementia and cognitive impairment due to the organic brain damage disease related directly to alcoholism.
  • CNS disorders can be attributed to a cholinergic deficiency, a dopaminergic deficiency, an adrenergic deficiency or a serotonergic deficiency.
  • the present invention is devoted to the provision novel modulators of the nicotinic and/or of the monoamine receptors, which modulators are useful for the treatment of diseases or disorders related to the cholinergic receptors, and in particular the nicotinic acetylcholine receptor (nAChR), the monoamine receptors 5- HTR, DAR and NER, and the biogenic amine transporters for 5-HT, DA and NE.
  • nAChR nicotinic acetylcholine receptor
  • NER nicotinic acetylcholine receptor
  • biogenic amine transporters for 5-HT, DA and NE for 5-HT, DA and NE.
  • the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
  • CNS central nervous system
  • PNS peripheral nervous system
  • the compounds of the invention may also be useful as diagnostic tools or monitoring agents in various diagnostic methods, and in particular for in vivo receptor imaging (neuroimaging), and they may be used in labelled or unlabelled form.
  • formulas represents a single or a double bond (an optionally double bond); n is 0, 1 , 2 or 3; m is 1 , 2 or 3; and R represents hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl.
  • compositions comprising a therapeutically effective amount of the chemical substance of the invention, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, together with at least one pharmaceutically-acceptable carrier or diluent.
  • the invention relates to the use of the chemical substance of the invention for the treatment, prevention or alleviation of a disease or a disorder or a condition, which is responsive to modulation of cholinergic receptors and/or monoamine receptors.
  • the invention provides methods of treatment, prevention or alleviation of diseases, disorders or conditions of a living animal body, which disease or disorder is responsive to modulation of cholinergic receptors and/or monoamine receptors, which method comprises the step of administering to such a living animal body, including a human, in need thereof a therapeutically effective amount of the chemical substance of the invention.
  • — represents a single or a double bond (an optionally double bond); n is O, 1 , 2 or 3; m is 1 , 2 or 3; and
  • R represents hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl.
  • the chemical substance of the invention is a benzo[b]thiophene derivative of Formula IA
  • the chemical substance of the invention is a benzo[b]thiophene derivative of Formula IA, wherein X represents a group of Formula II, wherein n is 0, 1 or 2; m is 1 , 2 or 3; and R represents hydrogen, alkyl, or aralkyl.
  • the chemical substance of the invention is a benzo[b]thiazole derivative of Formula IB, wherein X represents a group of Formula II, wherein n is 0, 1 or 2; m is 1 , 2 or 3; and R represents hydrogen, alkyl, or aralkyl.
  • X represents a group of Formula II, wherein n is 0, 1 or 2; m is 1 , 2 or 3; and R represents hydrogen, alkyl, or aralkyl.
  • X represents a group of Formula II, wherein n is 0, 1 or 2; m is 1 , 2 or 3; and R represents hydrogen, alkyl, or aralkyl.
  • the chemical substance of the invention is a benzo[b]thiophene derivative of Formula IA, wherein X represents a group of Formula III, wherein z z represents a double bond; n is 0 or 1 ; and R represents hydrogen, alkyl or aralkyl.
  • the benzo[b]thiophene derivative of Formula IA is -Benzo[b]thiophenyl-1 , 1 -dioxide)-8-H-8-azabicyclo[3.2.1 ]oct-2-ene; -Benzo[b]thiophenyl-1 ,1-dioxide)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene; -Benzo[b]thiophenyl-1 ,1-dioxide)-8-ethyl-8-azabicyclo[3.2.1]oct-2-ene; -Benzo[b]thiophenyl-1 , 1 -dioxide j-8-allyl-8-azabicyclo[3.2.1 ]oct-2-ene; -Benzo[b]thiophenyl-1 ,1-dioxide)-8-benzyl-8-azabicyclo[3.2.1]oct-2-ene; -Benzo[b]
  • the chemical substance of the invention is a benzo[b]thiazole derivative of Formula IB, wherein X represents a group of Formula III, wherein ⁇ n represents a double bond; n is 0 or 1 ; and R represents hydrogen, alkyl or aralkyl.
  • X represents a group of Formula III, wherein ⁇ n represents a double bond; n is 0 or 1 ; and R represents hydrogen, alkyl or aralkyl.
  • the chemical substance of the invention is a benzo[b]thiophene derivative of Formula IA, wherein X represents a group of Formula IV, wherein z z represents a double bond; n is 0 or 1 ; and R represents hydrogen or alkyl.
  • X represents a group of Formula IV, wherein z z represents a double bond; n is 0 or 1 ; and R represents hydrogen or alkyl.
  • the chemical substance of the invention is a benzo[b]thiazole derivative of Formula IB, wherein X represents a group of Formula IV, wherein TM represents a double bond; n is 0 or 1; and R represents hydrogen or alkyl.
  • the chemical substance of the invention is a benzo[b]thiophene derivative of Formula IA, wherein X represents a group of Formula V, wherein n is 0, 1 or 2; m is 1 or 2; and R represents hydrogen or alkyl.
  • benzo[b]thiophene derivative of Formula IA is ( ⁇ ) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-9-H-3,9-diazabicyclo-[4.2.1]-nonane;
  • the chemical substance of the invention is a benzo[b]thiazole derivative of Formula IB, wherein X represents a group of Formula V, wherein n is 0, 1 or 2; m is 1 or 2; and R represents hydrogen or alkyl.
  • benzo[b]thiazole derivative of Formula IB is ( ⁇ ) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-9-H-3,9-diazabicyclo-[4.2.1]-nonane;
  • the chemical substance of the invention is a benzo[b]thiophene derivative of Formula IA, wherein X represents a group of Formula VI, wherein n is 0 or 1 ; and R represents hydrogen, alkyl, phenyl or benzyl.
  • the chemical substance of the invention is a benzo[b]thiazole derivative of Formula IB, wherein X represents a group of Formula VI, wherein n is 0 or 1 ; and R represents hydrogen, alkyl, phenyl or benzyl.
  • benzo[b]thiazole derivative of Formula IB is ( ⁇ ) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-7-H-3,7-diazabicyclo[3.3.0]octane;
  • the chemical substance of the invention is a benzo[b]thiophene derivative of Formula IA, wherein X represents a group of Formula VII, wherein R represents hydrogen or alkyl.
  • benzo[b]thiophene derivative of Formula IA is ( ⁇ ) 2-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-(1S,4S)-(+)-5-H-2,5-diazabicyclo-[2.2.1]- heptane;
  • the chemical substance of the invention is a benzo[b]thiazole derivative of Formula IB, wherein X represents a group of Formula VII, wherein R represents hydrogen or alkyl.
  • benzo[b]thiazole derivative of Formula IB is (+) 2-(2-Benzo[b]thiazolyl-1 ,1-dioxideH1S,4S)-(+)-5-H-2,5-diazabicyclo-[2.2.1]- heptane; or
  • the chemical substance of the invention is a benzo[b]thiophene derivative of Formula IA, wherein X represents a group of Formula VIII, wherein TM represents a single bond or a double bond.
  • benzo[b]thiazole derivative of Formula IB is ( ⁇ ) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-quinuclidine; or
  • an alkyl group designates a univalent saturated, straight or branched hydrocarbon chain.
  • the hydrocarbon chain preferably contain of from one to eighteen carbon atoms (Ci-is-alkyl), more preferred of from one to six carbon atoms (C- ⁇ - 6 -alkyl; lower alkyl), including pentyl, isopentyl, neopentyl, tertiary pentyl, hexyl and isohexyl.
  • alkyl represents a C ⁇ -4 - alkyl group, including butyl, isobutyl, secondary butyl, and tertiary butyl.
  • alkyl represents a C ⁇ -3 -alkyl group, which may in particular be methyl, ethyl, propyl or isopropyl.
  • an alkenyl group designates a carbon chain containing one or more double bonds, including di-enes, tri-enes and poly-enes.
  • the alkenyl group of the invention comprises of from two to eight carbon atoms (C 2-8 -alkenyl), more preferred of from two to six carbon atoms (C 2- 6 -alkenyl), including at least one double bond.
  • the alkenyl group of the invention is ethenyl; 1- or 2-propenyl; 1-, 2- or 3-butenyl, or 1 ,3- butdienyl; 1-, 2-, 3-, 4- or 5-hexenyl, or 1 ,3-hexdienyl, or 1 ,3,5-hextrienyl; 1-, 2-, 3-, 4-, 5-, 6-, or 7-octenyl, or 1 ,3-octdienyl, or 1 ,3,5-octtrienyl, or 1 ,3,5,7-octtetraenyl.
  • an alkynyl group designates a carbon chain containing one or more triple bonds, including di-ynes, tri-ynes and poly-ynes.
  • the alkynyl group of the invention comprises of from two to eight carbon atoms (C 2-8 -alkynyl), more preferred of rom two to six carbon atoms (C 2- 6 -alkynyl), including at least one triple bond.
  • the alkynyl group of the invention is ethynyl; 1-, or 2-propynyl; 1-, 2-, or 3-butynyl, or 1 ,3- butdiynyl; 1-, 2-, 3-, 4-pentynyl, or 1 ,3-pentdiynyl; 1-, 2-, 3-, 4-, or 5-henynyl, or 1 ,3- hexdiynyl or 1 ,3,5-hextriynyl; 1-, 2-, 3-, 4-, 5- or 6-heptynyl, or 1 ,3-heptdiynyl, or 1 ,3,5- hepttriynyl; 1-, 2-, 3-, 4-, 5-, 6- or 7-octynyl, or 1 ,3-octdiynyl, or 1 ,3,5-octtriynyl, or 1,3,5,7-octtetraynyl.
  • a cycloalkyl group designates a cyclic alkyl group, preferably containing of from three to seven carbon atoms (C 3 - 7 -cycloalkyl), including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • a cycloalkyl-alkyl group designates a cycloalkyl group as defined above, which cycloalkyl group is substituted on an alkyl group as also defined above. Examples of preferred cycloalkyl-alkyl groups of the invention include cyclopropylmethyl and cyclopropylethyl.
  • an aryl group designates a monocyclic or polycyclic aromatic hydrocarbon group.
  • preferred aryl groups of the invention include phenyl, indenyl, naphthyl, azulenyl, fluorenyl, and anthracenyl.
  • an aralkyl group designates an aryl group as defined above, which aryl group is attached to an alkyl group as also defined above.
  • Examples of preferred aralkyl groups of the invention include benzyl.
  • the chemical compound of the invention may be provided in any form suitable for the intended administration. Suitable forms include pharmaceutically (i.e. physiologically) acceptable salts, and pre- or prodrug forms of the chemical compound of the invention.
  • Examples of pharmaceutically acceptable addition salts include, without limitation, the non-toxic inorganic and organic acid addition salts such as the hydrochloride derived from hydrochloric acid, the hydrobromide derived from hydrobromic acid, the nitrate derived from nitric acid, the perchlorate derived from perchloric acid, the phosphate derived from phosphoric acid, the sulphate derived from sulphuric acid, the formate derived from formic acid, the acetate derived from acetic acid, the aconate derived from aconitic acid, the ascorbate derived from ascorbic acid, the benzenesulphonate derived from benzensulphonic acid, the benzoate derived from benzoic acid, the cinnamate derived from cinnamic acid, the citrate derived from citric acid, the embonate derived from embonic acid, the enantate derived from enanthic acid, the fumarate derived from fuma
  • acids such as oxalic acid, which may not be considered pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining a chemical compound of the invention and its pharmaceutically acceptable acid addition salt.
  • Metal salts of a chemical compound of the invention include alkali metal salts such as the sodium salt of a chemical compound of the invention containing a carboxy group.
  • onium salts of N-containing compounds are also contemplated as pharmaceutically acceptable salts.
  • Preferred “onium salts” include the alkyl-onium salts, the cycloalkyl-onium salts, and the cycloalkylalkyl-onium salts.
  • the chemical compounds of the present invention may exist in (+) and (-) forms as well as in racemic forms ( ⁇ ).
  • the racemates of these isomers and the individual isomers themselves are within the scope of the present invention.
  • Racemic forms can be resolved into the optical antipodes by known methods and techniques.
  • One way of separating the diastereomeric salts is by use of an optically active acid, and liberating the optically active amine compound by treatment with a base.
  • Another method for resolving racemates into the optical antipodes is based upon chromatography on an optical active matrix.
  • Racemic compounds of the present invention can thus be resolved into their optical antipodes, e.g., by fractional crystallisation of d- or I- (tartrates, mandelates, or camphorsulphonate) salts for example.
  • the chemical compounds of the present invention may also be resolved by the formation of diastereomeric amides by reaction of the chemical compounds of the present invention with an optically active activated carboxylic acid such as that derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) camphanic acid or by the formation of diastereomeric carbamates by reaction of the chemical compound of the present invention with an optically active chloroformate or the like.
  • an optically active activated carboxylic acid such as that derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) camphanic acid
  • optical active compounds can also be prepared from optical active starting materials.
  • the chemical substances of the invention may be prepared by conventional methods for chemical synthesis, e.g. those described in the working examples.
  • the starting materials for the processes described in the present application are known or may readily be prepared by conventional methods from commercially available chemicals.
  • one compound of the invention can be converted to another compound of the invention using conventional methods.
  • the end products of the reactions described herein may be isolated by conventional techniques, e.g. by extraction, crystallisation, distillation, chromatography, etc.
  • the present invention relates to novel chemical substances, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors (nAChR), and modulators of the monoamine receptors, in particular the biogenic amine transporters 5-HT, DA and NE. Also preferred compounds of the invention show selective ⁇ 7 activity.
  • nAChR nicotinic acetylcholine receptors
  • modulators of the monoamine receptors in particular the biogenic amine transporters 5-HT, DA and NE.
  • preferred compounds of the invention show selective ⁇ 7 activity.
  • modulator covers agonists, partial agonists, antagonists and allosteric modulators of the receptor.
  • the compounds of the invention may be useful for the treatment of diseases or conditions as diverse as CNS related diseases, PNS related diseases, diseases related to smooth muscle contraction, endocrine disorders, diseases related to neuro-degeneration, diseases related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
  • the compounds of the invention are used for the treatment of diseases, disorders, or conditions relating to the central nervous system.
  • Such diseases or disorders includes anxiety, cognitive disorders, learning deficit, memory deficits and dysfunction, Alzheimer's disease, attention deficit, attention deficit hyperactivity disorder, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Gilles de la Tourette's syndrome, depression, mania, manic depression, schizophrenia, obsessive compulsive disorders (OCD), panic disorders, eating disorders such as anorexia nervosa, bulimia and obesity, narcolepsy, nociception, AIDS-dementia, senile dementia, periferic neuropathy, autism, dyslexia, tardive dyskinesia, hyperkinesia, epilepsy, bulimia, post-traumatic syndrome, social phobia, sleeping disorders, pseudodementia, Ganser's syndrome, pre-menstrual syndrome, late luteal phase syndrome, chronic fatigue syndrome, mutism, trichotillomania, and jet-lag.
  • OCD obsessive compulsive disorders
  • the compounds of the invention may be useful for the treatment of diseases, disorders, or conditions associated with smooth muscle contractions, including convulsive disorders, angina pectoris, premature labour, convulsions, diarrhoea, asthma, epilepsy, tardive dyskinesia, hyperkinesia, premature ejaculation, and erectile difficulty.
  • the compounds of the invention may be useful for the treatment of endocrine disorders, such as thyrotoxicosis, pheochromocytoma, hypertension and arrhythmias.
  • the compounds of the invention may be useful for the treatment of neurodegenerative disorders, including transient anoxia and induced neuro-degeneration.
  • the compounds of the invention may be useful for the treatment of inflammatory diseases, disorders, or conditions, including inflammatory skin disorders such as acne and rosacea, Chron's disease, inflammatory bowel disease, ulcerative colitis, and diarrhoea.
  • the compounds of the invention may be useful for the treatment of mild, moderate or even severe pain of acute, chronic or recurrent character, as well as pain caused by migraine, postoperative pain, and phantom limb pain.
  • the compounds of the invention may be useful for the treatment of withdrawal symptoms caused by termination of use of addictive substances.
  • addictive substances include nicotine containing products such as tobacco, opioids such as heroin, cocaine and morphine, benzodiazepines and benzodiazepine-like drugs, and alcohol.
  • addictive substances include nicotine containing products such as tobacco, opioids such as heroin, cocaine and morphine, benzodiazepines and benzodiazepine-like drugs, and alcohol.
  • Withdrawal from addictive substances is in general a traumatic experience characterised by anxiety and frustration, anger, anxiety, difficulties in concentrating, restlessness, decreased heart rate and increased appetite and weight gain.
  • treatment covers treatment, prevention, prophylactics and alleviation of withdrawal symptoms and abstinence as well as treatment resulting in a voluntary diminished intake of the addictive substance.
  • the compounds of the invention are used as diagnostic agents, e.g. for the identification and localisation of nicotinic receptors in various tissues.
  • Neuroimaging e.g. for the identification and localisation of nicotinic receptors in various tissues.
  • the chemical substances of the invention may be useful as diagnostic tools or monitoring agents in various diagnostic methods, and in particular for in vivo receptor imaging (neuroimaging).
  • a method for the non-invasive determination of the distribution of a tracer compound inside a whole, intact living animal or human body using a physical detection method is provided.
  • a tracer compound is a compound of the invention, or any of its enantiomers or any mixture thereof, an N oxide thereof, a pharmaceutically 10 acceptable salt thereof, in a labelled or un-labelled form.
  • the physical detection method is selected from PET, SPECT; MRS, MRI, CAT, or combinations thereof.
  • the labelled compound of the invention preferably contains at least one radionuclide as a label. Positron emitting radionuclides are all candidates for usage. In 15 the context of this invention the radionuclide is preferably selected from 2 H (deuterium), 3 H (tritium), 11 C, 13 C, 14 C, 15 0, 13 N, 123 l, 125 l, 131 l, 18 F and 99m Tc.
  • labelling agents which can be used in the preparation of the labelled compounds of the present invention is [ 11 C]0 2 , 18 F, and Nal with different isotopes of Iodine. 20
  • [ 11 C]0 2 may be converted to a [ 11 C]-methylating agent, such as [ 11 C]H 3 I or [ 11 C]-methyl triflate.
  • the tracer compound can be selected in accordance with the detection method chosen.
  • the labelled or unlabelled compound of the 25 invention can be detected by a suitable spectroscopic method, in particular UV spectroscopy and/or fluorescence spectroscopy.
  • the compounds of the invention labelled by incorporation of a isotope into the molecule which may in particular be an isotope of the naturally occurring atoms including 2 H (deuterium), 3 H (tritium), 11 C, 13 C, 14 C,
  • the physical method for detecting said tracer compound of the present invention is selected from Position Emission
  • PET Single Photon Imaging Computed Tomography
  • SPECT Single Photon Imaging Computed Tomography
  • Computed Axial X-ray Tomography CAT
  • CAT Computed Axial X-ray Tomography
  • a diagnostically effective amount of a labelled or unlabelled compound of the invention is administered to a living body, including a human.
  • the compounds of the invention is believed to be particularly suited for in vivo receptor imaging (neuroimaging).
  • the physical method for detecting the compound of the invention is Position Emission Tomography (PET). It is currently believed that the diagnostically effective amount of the labelled or unlabelled compound of the invention, to be administered before conducting the in vivo method for the invention, is within a range of from 0.1 ng to 100 mg per kg body weight, preferably within a range of from 1 ng to 10 mg per kg body weight.
  • the invention provides novel pharmaceutical compositions comprising a therapeutically effective amount of the chemical substance of the invention. While a chemical compound of the invention for use in therapy may be administered in the form of the raw chemical compound, it is preferred to introduce the active ingredient, optionally in the form of a physiologically acceptable salt, in a pharmaceutical composition together with one or more adjuvants, excipients, carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries.
  • the invention provides pharmaceutical compositions comprising the chemical substance of the invention, or a pharmaceutically acceptable salt or derivative thereof, together with one or more pharmaceutically acceptable carriers therefore, and, optionally, other therapeutic and/or prophylactic ingredients, know and used in the art.
  • the carriers must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the recipient thereof.
  • the pharmaceutical composition of the invention may be administered by any convenient route, which suits the desired therapy.
  • Preferred routes of administration include oral administration, in particular in tablet, in capsule, in drage, in powder, or in liquid form, and parenteral administration, in particular cutaneous, subcutaneous, intramuscular, or intravenous injection.
  • the pharmaceutical composition of the invention can be manufactured by any skilled person by use of standard methods and conventional techniques appropriate to the desired formulation. When desired, compositions adapted to give sustained release of the active ingredient may be employed.
  • compositions containing of from about 0.1 to about 500 mg of active ingredient per individual dose preferably of from about 1 to about 100 mg, most preferred of from about 1 to about 10 mg, are suitable for therapeutic treatments.
  • the active ingredient may be administered in one or several doses per day.
  • a satisfactory result can, in certain instances, be obtained at a dosage as low as 0.1 ⁇ g/kg i.v. and 1 ⁇ g/kg p.o.
  • the upper limit of the dosage range is presently considered to be about 10 mg/kg i.v. and 100 mg/kg p.o.
  • Preferred ranges are from about 0.1 ⁇ g/kg to about 10 mg/kg/day i.v., and from about 1 ⁇ g/kg to about 100 mg/kg/day p.o.
  • the chemical substances of the present invention are valuable nicotinic and monoamine receptor modulators, and therefore useful for the treatment of a range of ailments involving cholinergic dysfunction as well as a range of disorders responsive to the action of nAChR modulators.
  • the invention provides a method for the treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disease, disorder or condition is responsive to modulation of cholinergic receptors and/or monoamine receptors, and which method comprises administering to such a living animal body, including a human, in need thereof an effective amount of a compound of the invention.
  • the disease, disorder or condition relates to the central nervous system.
  • the disease, disorder or condition is anxiety, cognitive disorders, learning deficit, memory deficits and dysfunction, Alzheimer's disease, attention deficit, attention deficit hyperactivity disorder, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Gilles de la Tourette's syndrome, depression, mania, manic depression, schizophrenia, obsessive compulsive disorders (OCD), panic disorders, eating disorders such as anorexia nervosa, bulimia and obesity, narcolepsy, nociception, AIDS-dementia, senile dementia, periferic neuropathy, autism, dyslexia, tardive dyskinesia, hyperkinesia, epilepsy, bulimia, post-traumatic syndrome, social phobia, sleeping disorders, pseudodementia, Ganser's syndrome, pre-menstrual syndrome, late luteal phase syndrome, chronic fatigue syndrome, mutism, trichotillomania, and jet-lag.
  • OCD obsessive compulsive disorders
  • the disease, disorder or condition are associated with smooth muscle contractions, including convulsive disorders, angina pectoris, premature labour, convulsions, diarrhoea, asthma, epilepsy, tardive dyskinesia, hyperkinesia, premature ejaculation, and erectile difficulty.
  • the disease, disorder or condition is related to the endocrine system, such as thyrotoxicosis, pheochromocytoma, hypertension and arrhythmias.
  • the disease, disorder or condition is a neurodegenerative disorders, including transient anoxia and induced neuro- degeneration.
  • the disease, disorder or condition is an inflammatory disorder, including inflammatory skin disorders such as acne and rosacea, Chron's disease, inflammatory bowel disease, ulcerative colitis, and diarrhoea.
  • the disease, disorder or condition is mild, moderate or even severe pain of acute, chronic or recurrent character, as well as pain caused by migraine, postoperative pain, and phantom limb pain.
  • the disease, disorder or condition is associated with withdrawal symptoms caused by termination of use of addictive substances, including nicotine containing products such as tobacco, opioids such as heroin, cocaine and morphine, benzodiazepines and benzodiazepine-like drugs, and alcohol.
  • addictive substances including nicotine containing products such as tobacco, opioids such as heroin, cocaine and morphine, benzodiazepines and benzodiazepine-like drugs, and alcohol.
  • suitable dosage ranges are 0.1 to 1000 milligrams daily, 10-500 milligrams daily, and especially 30-100 milligrams daily, dependent as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge.
  • a satisfactory result can, in certain instances, be obtained at a dosage as low as 0.005 mg/kg i.v. and 0.01 mg/kg p.o.
  • the upper limit of the dosage range is about 10 mg/kg i.v. and 100 mg/kg p.o.
  • Preferred ranges are from about 0.001 to about 1 mg/kg i.v. and from about 0.1 to about 10 mg/kg p.o.
  • loct-2-ene hydrochloric acid salt To a mixture of benzo[b]thiophene (20.2 g, 151 mmol) and diethyl ether
  • (+W3-(2-Benzorb1thiophenyl-1.1 -dioxideV8-allyl-8-azabicyclo[3.2.1 ]oct-2-ene (Compound 3) A mixture of ( ⁇ )3-(2-benzo[b]thiophenyl-1 ,1-dioxide)-8-H-8- azabicyclo[3.2.1]oct-2-ene (0.16 g, 0.58 mmol), 3-bromo-1-propene (54 ul, 0.64 mmol), diisopropylethylamine (102 ul, 0.58 mmol), DMF (10 ml) was stirred at 80°C for 2 days. Aqueous sodium hydroxide (20 ml, 1 M) was added.
  • ⁇ -Bungarotoxine is a peptide isolated from the venom of the Elapidae snake Bungarus multicinctus. It has high affinity for neuronal and neuromuscular nicotinic receptors, where it acts as a potent antagonist.
  • H- ⁇ -Bungarotoxine labels nicotinic acetylcholine receptors formed by the ⁇ 7 subunit isoform found in brain and the ⁇ -i isoform in the neuromuscular junction.
  • Preparations are performed at 0-4°C. Cerebral cortices from male Wistar rats (150-250 g) are homogenised for 10 seconds in 15 ml of 20 mM Hepes buffer containing 118 mM NaCI, 4.8 mM KCI, 1.2 mM MgS0 4 and 2.5 mM CaCI 2 (pH 7.5) using an Ultra-Turrax homogeniser. The tissue suspension is subjected to centrifugation at 27,000 x g for 10 minutes.
  • the supernatant is discarded and the pellet is washed twice by centrifugation at 27,000 x g for 10 minutes in 20 ml of fresh buffer, and the final pellet is then re-suspended in fresh buffer containing 0.01 % BSA (35 ml per g of original tissue) and used for binding assays.
  • the amount of radioactivity on the filters is determined by conventional liquid scintillation counting. Specific binding is total binding minus non-specific binding.
  • the test value is given as an IC 50 (the concentration of the test substance which inhibits the specific binding of 3 H- ⁇ -bungarotoxin by 50%).
  • Serotonin transporters/uptake sites on nerve terminals presumably function to terminate neuronal signaling by removing serotonin from the synaptic cleft.
  • the activity of the serotonin transporter integral protein can be measured in vitro by synaptosomal uptake of 3 H-5-hydroxytryptamine (5-HT, serotonin).
  • Preparations are performed at 0-4°C. Cerebral cortices from male Wistar rats (150-200 g) are homogenized for 5-10 seconds in 100 volumes of ice-cold 0.32 M sucrose containing 1 mM pargyline, using a motor driven teflon pestle in a glass homogenizing vessel. Monoamine oxidase activity is inhibited in the presence of pargyline.
  • the homogenate is subjected to centrifugation at 1000 x g for 10 minutes.
  • the resulting supernatant is then centrifuged at 27,000 x g for 50 minutes and the supernatant is discarded.
  • the pellet (P 2 ) is re-suspended in oxygenated (equilibrated with an atmosphere of 96% 0 2 : 4% C0 2 for at least 30 minutes) Krebs-Ringer incubation buffer (1000 ml per g of original tissue) at pH 7.2 containing 122 mM NaCI, 0.16 mM EDTA, 4.8 mM KCI, 12.7 mM Na 2 HP0 4 , 3.0 mM NaH 2 P0 4 , 1.2 mM MgS0 4 , 1 mM CaCI 2 , 10 mM glucose and 1 mM ascorbic acid.
  • the amount of radioactivity on the filters is determined by conventional liquid scintillation counting. Specific uptake is calculated as the difference between total uptake and non-specific uptake.
  • IC 50 the concentration ( ⁇ M) of the test substance which inhibits the specific binding of 3 H-5-HT by 50%.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention relates to novel compounds that are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

Description

NOVEL COMPOUNDS, THEIR PREPARATION AND USE
TECHNICAL FIELD
The present invention relates to novel compounds that are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters.
Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
BACKGROUND ART
The endogenous cholinergic neurotransmitter, acetylcholine, exert its biological effect via two types of cholinergic receptors, the muscarinic Acetyl Choline Receptors (mAChR) and the nicotinic Acetyl Choline Receptors (nAChR).
As it is well established that muscarinic acetylcholine receptors dominate quantitatively over nicotinic acetylcholine receptors in the brain area important to memory and cognition, and much research aimed at the development of agents for the treatment of memory related disorders have focused on the synthesis of muscarinic acetylcholine receptor modulators.
Recently, however, an interest in the development of nAChR modulators has emerged. Several diseases are associated with degeneration of the cholinergic system i.e. senile dementia of the Alzheimer type, vascular dementia and cognitive impairment due to the organic brain damage disease related directly to alcoholism. Indeed several CNS disorders can be attributed to a cholinergic deficiency, a dopaminergic deficiency, an adrenergic deficiency or a serotonergic deficiency.
SUMMARY OF THE INVENTION
The present invention is devoted to the provision novel modulators of the nicotinic and/or of the monoamine receptors, which modulators are useful for the treatment of diseases or disorders related to the cholinergic receptors, and in particular the nicotinic acetylcholine receptor (nAChR), the monoamine receptors 5- HTR, DAR and NER, and the biogenic amine transporters for 5-HT, DA and NE. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
The compounds of the invention may also be useful as diagnostic tools or monitoring agents in various diagnostic methods, and in particular for in vivo receptor imaging (neuroimaging), and they may be used in labelled or unlabelled form.
In its first aspect the invention provides novel chemical substances represented by the general Formula I
Figure imgf000004_0001
any of its enantiomers or any mixture of enantiomers, or a pharmaceutically-acceptable addition salt thereof, wherein A, B, D, E and G, independently of each another, represent a carbon (C) or a nitrogen (N) atom, constituting an aromatic ring system; and X represents a group of Formula ll
Figure imgf000004_0002
R a group of Formula
Figure imgf000004_0003
a group of Formula IV
Figure imgf000004_0004
a group of Formula V
Figure imgf000005_0001
a group of Formula VI
Figure imgf000005_0002
a group of Formula VII
Figure imgf000005_0003
or a group of Formula VIII
Figure imgf000005_0004
in which formulas =. represents a single or a double bond (an optionally double bond); n is 0, 1 , 2 or 3; m is 1 , 2 or 3; and R represents hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl.
In another aspect the invention provides pharmaceutical compositions comprising a therapeutically effective amount of the chemical substance of the invention, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, together with at least one pharmaceutically-acceptable carrier or diluent.
In yet another aspect the invention relates to the use of the chemical substance of the invention for the treatment, prevention or alleviation of a disease or a disorder or a condition, which is responsive to modulation of cholinergic receptors and/or monoamine receptors. In still another aspect the invention provides methods of treatment, prevention or alleviation of diseases, disorders or conditions of a living animal body, which disease or disorder is responsive to modulation of cholinergic receptors and/or monoamine receptors, which method comprises the step of administering to such a living animal body, including a human, in need thereof a therapeutically effective amount of the chemical substance of the invention.
Other objects of the invention will be apparent to the person skilled in the art from the following detailed description and examples. DETAILED DISCLOSURE OF THE INVENTION
In its first aspect the present invention provides novel chemical substances represented by the general Formula I
Figure imgf000006_0001
any of its enantiomers or any mixture of enantiomers, or a pharmaceutically-acceptable addition salt thereof, wherein A, B, D, E and G, independently of each another, represent a carbon (C) or a nitrogen (N) atom, and wherein no more than two of B, D, E and G represent nitrogen atoms while the remainder of B, D, E and G represent carbon atoms, thereby constituting an aromatic ring system; and X represents a group of Formula II
Figure imgf000006_0002
R a group of Formula III
Figure imgf000006_0003
a group of Formula IV
Figure imgf000006_0004
a group of Formula V
Figure imgf000006_0005
a group of Formula VI
Figure imgf000006_0006
a group of Formula VII
Figure imgf000007_0001
or a group of Formula VIII
Figure imgf000007_0002
in which formulas
— represents a single or a double bond (an optionally double bond); n is O, 1 , 2 or 3; m is 1 , 2 or 3; and
R represents hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl.
In a preferred embodiment, the chemical substance of the invention is a benzo[b]thiophene derivative of Formula IA
Figure imgf000007_0003
a benzo[b]thiazole derivative of Formula IB
Figure imgf000007_0004
a thienopyridine derivative of Formula IC
Figure imgf000007_0005
a thienopyridine derivative of Formula ID
Figure imgf000007_0006
a thienopyridine derivative of Formula IE
Figure imgf000007_0007
or a thienopyridine derivative of Formula IF
Figure imgf000008_0001
in which formulas
A and X are as defined above. In a more preferred embodiment, the chemical substance of the invention is a benzo[b]thiophene derivative of Formula IA, wherein X represents a group of Formula II, wherein n is 0, 1 or 2; m is 1 , 2 or 3; and R represents hydrogen, alkyl, or aralkyl.
In a most preferred embodiment the benzo[b]thiophene derivative of the invention is
(±) ■(2-Benzo[b ]thiophenyl- 1 -dioxide imidazolidine; (±) -(2-Benzo[b jthiophenyl- 1 -dioxide 3-methyl-imidazolidine; (±) ■(2-Benzo[bthiophenyl- 1 -dioxide -1.3-diazacyclohexane; (±) -(2-Benzo[b Jthiophenyl- 1 -dioxide 3-methyl-1.3-diazacyclohexane; (±) -(2-Benzo[b ι]thiophenyl- 1 -dioxide piperazine; (±) -(2-Benzo[b ]thiophenyl- 1 -dioxide 4-methyl-piperazine; (±) -(2-Benzo[b thiophenyI- 1 -dioxide ι-4-ethyl-piperazine; (±) -(2-Benzo[b thiophenyl- 1 -dioxide -4-benzyl-piperazine; (±) -(2-Benzo[b ]thiophenyl- 1 -dioxide homopiperazine; (±) -(2-Benzo[b Jthiophenyl- 1 -dioxide 4-methyl-homopiperazine; (±) -(2-Benzo[b ijthiophenyl- 1 -dioxide ι-4-ethyl-homopiperazine; (±) -(2-Benzo[b ijthiophenyl- 1 -dioxide ι-4-benzyl-homopiperazine; (±) -(2-Benzo[ ι]thiophenyl- 1 -dioxide ι-1 ,4-diazacyclooctane; (±) -(2-Benzo[b ]thiophenyl- 1 -dioxide 4-methyl-1 ,4-diazacyclooctane; (±) -(2-Benzo[b ]thiophenyl- 1 -dioxide 4-ethyl-1 ,4-diazacyclooctane; (±) -(2-Benzo[b ι]thiophenyI- 1 -dioxide 4-benzyl-1 ,4-diazacyclooctane; (±) -(2-Benzo[b ]thiophenyl- 1 -dioxide -1 ,5-diazacyclooctane; (±) -(2-Benzo[b Jthiophenyl- 1 -dioxide 5-methyl-1 ,5-diazacyclooctane; (±) -(2-Benzo[b thiophenyl- 1 -dioxide 5-ethyl-1 ,5-diazacyclooctane; or (±) -(2-Benzo[b ]thiophenyl- 1 -dioxide) >-5-benzyl-1 ,5-diazacyclooctane; or a pharmaceutically-accep able addition salt thereof. In another preferred embodiment, the chemical substance of the invention is a benzo[b]thiazole derivative of Formula IB, wherein X represents a group of Formula II, wherein n is 0, 1 or 2; m is 1 , 2 or 3; and R represents hydrogen, alkyl, or aralkyl. In a most preferred embodiment the benzo[b]thiazole derivative of the
imidazolidine; 3-methyl-imidazolidine; 1.3-diazacyclohexane; 3-methyl-1.3-diazacyclohexane; piperazine; 4-methyl-piperazine; 4-ethyl-piperazine; 4-benzyI-piperazine; homopiperazine; 4-methyl-homopiperazine; 4-ethyl-homopiperazine; 4-benzyl-homopiperazine; 1 ,4-diazacyclooctane; 4-methyl-1 ,4-diazacyclooctane; 4-ethyl-1 ,4-diazacyclooctane; 4-benzyl-1 ,4-diazacyclooctane; 1 ,5-diazacyclooctane; 5-methyI-1 ,5-diazacyclooctane; 5-ethyl-1 ,5-diazacyclooctane; or
Figure imgf000009_0001
5-benzyl-1 ,5-diazacyclooctane; or a pharmaceutically-acceptable addition salt thereof.
In a third preferred embodiment, the chemical substance of the invention is a benzo[b]thiophene derivative of Formula IA, wherein X represents a group of Formula III, wherein z z represents a double bond; n is 0 or 1 ; and R represents hydrogen, alkyl or aralkyl.
In a most preferred embodiment the benzo[b]thiophene derivative of Formula IA is -Benzo[b]thiophenyl-1 , 1 -dioxide)-8-H-8-azabicyclo[3.2.1 ]oct-2-ene; -Benzo[b]thiophenyl-1 ,1-dioxide)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene; -Benzo[b]thiophenyl-1 ,1-dioxide)-8-ethyl-8-azabicyclo[3.2.1]oct-2-ene; -Benzo[b]thiophenyl-1 , 1 -dioxide j-8-allyl-8-azabicyclo[3.2.1 ]oct-2-ene; -Benzo[b]thiophenyl-1 ,1-dioxide)-8-benzyl-8-azabicyclo[3.2.1]oct-2-ene; -Benzo[b]thiophenyl-1 ,1-dioxide)-9-H-9-azabicycIo[3.3.1]non-2-ene; -Benzo[b]thiophenyl-1 ,1-dioxide)-9-methyl-9-azabicyclo[3.3.1]non-2-ene; -Benzo[b]thiophenyl-1 ,1-dioxide)-9-ethyl-9-azabicyclo[3.3.1]non-2-ene;
Figure imgf000009_0002
-Benzo[b]thiophenyl-1 ,1-dioxide)-9-benzyl-9-azabicyclo[3.3.1]non-2-ene; or a pharmaceutically-acceptable addition salt thereof. In a fourth preferred embodiment, the chemical substance of the invention is a benzo[b]thiazole derivative of Formula IB, wherein X represents a group of Formula III, wherein ^n represents a double bond; n is 0 or 1 ; and R represents hydrogen, alkyl or aralkyl. In a most preferred embodiment the benzo[b]thiazole derivative of Formula
IB is
(+) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-8-H-8-azabicyclo[3.2.1]oct-2-ene; (+) 3-(2-Benzo[b]thiazolyl-1 ,1 -dioxide)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene; (±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-8-ethyl-8-azabicyclo[3.2.1]oct-2-ene; (+) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-8-benzyl-8-azabicyclo[3.2.1]oct-2-ene;
(+) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-9-H-9-azabicyclo[3.3.1]non-2-ene; (±) 3-(2-Benzo[b]thiazolyl-1 , 1 -dioxide)-9-methyI-9-azabicyclo[3.3.1 ]non-2-ene; (+) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-9-ethyl-9-azabicyclo[3.3.1]non-2-ene; or (+) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-9-benzyl-9-azabicyclo[3.3.1]non-2-ene; or a pharmaceutically-acceptable addition salt thereof.
In a fifth preferred embodiment, the chemical substance of the invention is a benzo[b]thiophene derivative of Formula IA, wherein X represents a group of Formula IV, wherein z z represents a double bond; n is 0 or 1 ; and R represents hydrogen or alkyl. In a most preferred embodiment the benzo[b]thiophene derivative of
Formula IA is
(±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-7-H-7-azabicyclo[3.3.0]oct-2-ene; (±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-7-methyl-7-azabicyclo[3.3.0]oct-2-ene; (±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-7-ethyl-7-azabicyclo[3.3.0]oct-2-ene; or (±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-7-benzyl-7-azabicyclo[3.3.0]oct-2-ene; or a pharmaceutically-acceptable addition salt thereof. In a sixth preferred embodiment, the chemical substance of the invention is a benzo[b]thiazole derivative of Formula IB, wherein X represents a group of Formula IV, wherein ™ represents a double bond; n is 0 or 1; and R represents hydrogen or alkyl.
In a most preferred embodiment the benzo[b]thiazole derivative of Formula IB is
(±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-7-H-7-azabicyclo[3.3.0]oct-2-ene; (±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-7-methyl-7-azabicyclo[3.3.0]oct-2-ene; (±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-7-ethyl-7-azabicyclo[3.3.0]oct-2-ene; or
(±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-7-benzyl-7-azabicyclo[3.3.0]oct-2-ene; or a pharmaceutically-acceptable addition salt thereof.
In a seventh preferred embodiment, the chemical substance of the invention is a benzo[b]thiophene derivative of Formula IA, wherein X represents a group of Formula V, wherein n is 0, 1 or 2; m is 1 or 2; and R represents hydrogen or alkyl.
In a most preferred embodiment the benzo[b]thiophene derivative of Formula IA is (±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-9-H-3,9-diazabicyclo-[4.2.1]-nonane;
(+) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-9-methyl-3,9-diazabicyclo-[4.2.1]- nonane;
(+) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-9-ethyl-3,9-diazabicyclo-[4.2.1]-nonane; (±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-10-H-3,10-diazabicyclo-[4.3.1]-decane; (±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-10-methyl-3,10-diazabicyclo-[4.3.1]- decane;
(±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-10-ethyl-3,10-diazabicyclo-[4.3.1]- decane; or a pharmaceutically-acceptable addition salt thereof. In an eight preferred embodiment, the chemical substance of the invention is a benzo[b]thiazole derivative of Formula IB, wherein X represents a group of Formula V, wherein n is 0, 1 or 2; m is 1 or 2; and R represents hydrogen or alkyl.
In a most preferred embodiment the benzo[b]thiazole derivative of Formula IB is (±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-9-H-3,9-diazabicyclo-[4.2.1]-nonane;
(+) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-9-methyl-3,9-diazabicyclo-[4.2.1]-nonane; (±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-9-ethyl-3,9-diazabicyclo-[4.2.1]-nonane; (+) 3-(2-Benzo[b]thiazolyl-1 , 1 -dioxide)-10-H-3, 10-diazabicyclo-[4.3.1 ]-decane; (+) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-10-methyl-3,10-diazabicyclo-[4.3.1]- decane; or
(±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-10-ethyl-3,10-diazabicyclo-[4.3.1]-decane; or a pharmaceutically-acceptable addition salt thereof.
In a ninth preferred embodiment, the chemical substance of the invention is a benzo[b]thiophene derivative of Formula IA, wherein X represents a group of Formula VI, wherein n is 0 or 1 ; and R represents hydrogen, alkyl, phenyl or benzyl.
In a most preferred embodiment the benzo[b]thiophene derivative of Formula IA is
(±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-7-H-3,7-diazabicyclo[3.3.0]octane;
(±) 3-(2-Benzo[b]thiophenyI-1 1-dioxide)-7-methyl-3,7-diazabicyclo[3.3.0]octane; (±) 3-(2-Benzo[b]thiophenyl-1 1-dioxide)-7-ρhenyl-3,7-diazabicyclo[3.3.0]octane;
(±) 3-(2-Benzo[b]thiophenyl-1 1-dioxide)-7-benzyl-3,7-diazabicyclo[3.3.0]octane; (±) 3-(2-Benzo[b]thiophenyl-1 1-dioxide)-7-H-3,7-diazabicyclo[3.3.1]nonane; (±) 3-(2-Benzo[b]thiophenyl-1 1-dioxide)-7-methyl-3,7- diazabicyclo[3.3.1]nonane; (±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-7-phenyl-3,7- diazabicyclo[3.3.1]nonane;
(±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-7-benzyl-3,7-diazabicyclo[3.3.1]nonane; or a pharmaceutically-acceptable addition salt thereof. In a tenth preferred embodiment, the chemical substance of the invention is a benzo[b]thiazole derivative of Formula IB, wherein X represents a group of Formula VI, wherein n is 0 or 1 ; and R represents hydrogen, alkyl, phenyl or benzyl.
In a most preferred embodiment the benzo[b]thiazole derivative of Formula IB is (±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-7-H-3,7-diazabicyclo[3.3.0]octane;
(±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-7-methyl-3,7-diazabicyclo[3.3.0]octane; (±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-7-phenyl-3,7-diazabicyclo[3.3.0]octane; (±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-7-benzyl-3,7-diazabicyclo[3.3.0]octane; (±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-7-H-3,7-diazabicycio[3.3.1]nonane; (±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-7-methyl-3,7-diazabicyclo[3.3.1]nonane;
(±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-7-phenyl-3,7-diazabicyclo[3.3.1]nonane; or
(±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-7-benzyl-3,7-diazabicyclo[3.3.1]nonane; or a pharmaceutically-acceptable addition salt thereof. In an eleventh preferred embodiment, the chemical substance of the invention is a benzo[b]thiophene derivative of Formula IA, wherein X represents a group of Formula VII, wherein R represents hydrogen or alkyl.
In a most preferred embodiment the benzo[b]thiophene derivative of Formula IA is (±) 2-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-(1S,4S)-(+)-5-H-2,5-diazabicyclo-[2.2.1]- heptane;
(±) 2-(2-Benzo[b]thiophenyl-1 , 1 -dioxide)-(1 S,4S)-(+)-5-methyl-2,5-diazabicyclo- [2.2.1]-heptane; or a pharmaceutically-acceptable addition salt thereof. In a twelve preferred embodiment, the chemical substance of the invention is a benzo[b]thiazole derivative of Formula IB, wherein X represents a group of Formula VII, wherein R represents hydrogen or alkyl.
In a most preferred embodiment the benzo[b]thiazole derivative of Formula IB is (+) 2-(2-Benzo[b]thiazolyl-1 ,1-dioxideH1S,4S)-(+)-5-H-2,5-diazabicyclo-[2.2.1]- heptane; or
(±) 2-(2-Benzo[b]thiazolyl-1 )1-dioxide)-(1S,4S)-(+)-5-methyl-2,5-diazabicyclo- [2.2.1]-heptane; or a pharmaceutically-acceptable addition salt thereof. In a thirteenth preferred embodiment, the chemical substance of the invention is a benzo[b]thiophene derivative of Formula IA, wherein X represents a group of Formula VIII, wherein ™ represents a single bond or a double bond.
In a most preferred embodiment the benzo[b]thiophene derivative of Formula IA is
(±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-quinuclidine; (±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-quinuclidine-2-ene; or (±)-3-(2-Benzothiophenyl-1 , 1 -dioxide)-quinuclidine-2-ene-N-methyl; or a pharmaceutically-acceptable addition salt thereof. In a fourteenth preferred embodiment, the chemical substance of the invention is a benzo[b]thiazole derivative of Formula IB, wherein X represents a group of Formula VIM, wherein = represents a single bond or a double bond.
In a most preferred embodiment the benzo[b]thiazole derivative of Formula IB is (±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-quinuclidine; or
(±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-quinuclidine-2-ene; or a pharmaceutically-acceptable addition salt thereof.
Definition of Substituents In the context of this invention an alkyl group designates a univalent saturated, straight or branched hydrocarbon chain. The hydrocarbon chain preferably contain of from one to eighteen carbon atoms (Ci-is-alkyl), more preferred of from one to six carbon atoms (C-ι-6-alkyl; lower alkyl), including pentyl, isopentyl, neopentyl, tertiary pentyl, hexyl and isohexyl. In a preferred embodiment alkyl represents a Cι-4- alkyl group, including butyl, isobutyl, secondary butyl, and tertiary butyl. In another preferred embodiment of this invention alkyl represents a Cι-3-alkyl group, which may in particular be methyl, ethyl, propyl or isopropyl.
In the context of this invention an alkenyl group designates a carbon chain containing one or more double bonds, including di-enes, tri-enes and poly-enes. In a preferred embodiment the alkenyl group of the invention comprises of from two to eight carbon atoms (C2-8-alkenyl), more preferred of from two to six carbon atoms (C2- 6-alkenyl), including at least one double bond. In a most preferred embodiment the alkenyl group of the invention is ethenyl; 1- or 2-propenyl; 1-, 2- or 3-butenyl, or 1 ,3- butdienyl; 1-, 2-, 3-, 4- or 5-hexenyl, or 1 ,3-hexdienyl, or 1 ,3,5-hextrienyl; 1-, 2-, 3-, 4-, 5-, 6-, or 7-octenyl, or 1 ,3-octdienyl, or 1 ,3,5-octtrienyl, or 1 ,3,5,7-octtetraenyl.
In the context of this invention an alkynyl group designates a carbon chain containing one or more triple bonds, including di-ynes, tri-ynes and poly-ynes. In a preferred embodiment the alkynyl group of the invention comprises of from two to eight carbon atoms (C2-8-alkynyl), more preferred of rom two to six carbon atoms (C2- 6-alkynyl), including at least one triple bond. In its most preferred embodiment the alkynyl group of the invention is ethynyl; 1-, or 2-propynyl; 1-, 2-, or 3-butynyl, or 1 ,3- butdiynyl; 1-, 2-, 3-, 4-pentynyl, or 1 ,3-pentdiynyl; 1-, 2-, 3-, 4-, or 5-henynyl, or 1 ,3- hexdiynyl or 1 ,3,5-hextriynyl; 1-, 2-, 3-, 4-, 5- or 6-heptynyl, or 1 ,3-heptdiynyl, or 1 ,3,5- hepttriynyl; 1-, 2-, 3-, 4-, 5-, 6- or 7-octynyl, or 1 ,3-octdiynyl, or 1 ,3,5-octtriynyl, or 1,3,5,7-octtetraynyl.
In the context of this invention a cycloalkyl group designates a cyclic alkyl group, preferably containing of from three to seven carbon atoms (C3-7-cycloalkyl), including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. In the context of this invention a cycloalkyl-alkyl group designates a cycloalkyl group as defined above, which cycloalkyl group is substituted on an alkyl group as also defined above. Examples of preferred cycloalkyl-alkyl groups of the invention include cyclopropylmethyl and cyclopropylethyl.
In the context of this invention an aryl group designates a monocyclic or polycyclic aromatic hydrocarbon group. Examples of preferred aryl groups of the invention include phenyl, indenyl, naphthyl, azulenyl, fluorenyl, and anthracenyl.
In the context of this invention an aralkyl group designates an aryl group as defined above, which aryl group is attached to an alkyl group as also defined above. Examples of preferred aralkyl groups of the invention include benzyl.
Pharmaceutically Acceptable Salts
The chemical compound of the invention may be provided in any form suitable for the intended administration. Suitable forms include pharmaceutically (i.e. physiologically) acceptable salts, and pre- or prodrug forms of the chemical compound of the invention.
Examples of pharmaceutically acceptable addition salts include, without limitation, the non-toxic inorganic and organic acid addition salts such as the hydrochloride derived from hydrochloric acid, the hydrobromide derived from hydrobromic acid, the nitrate derived from nitric acid, the perchlorate derived from perchloric acid, the phosphate derived from phosphoric acid, the sulphate derived from sulphuric acid, the formate derived from formic acid, the acetate derived from acetic acid, the aconate derived from aconitic acid, the ascorbate derived from ascorbic acid, the benzenesulphonate derived from benzensulphonic acid, the benzoate derived from benzoic acid, the cinnamate derived from cinnamic acid, the citrate derived from citric acid, the embonate derived from embonic acid, the enantate derived from enanthic acid, the fumarate derived from fumaric acid, the glutamate derived from glutamic acid, the glycolate derived from glycolic acid, the lactate derived from lactic acid, the maleate derived from maleic acid, the malonate derived from malonic acid, the mandelate derived from mandelic acid, the methanesulphonate derived from methane sulphonic acid, the naphthalene-2-sulphonate derived from naphtalene-2-sulphonic acid, the phthalate derived from phthalic acid, the salicylate derived from salicylic acid, the sorbate derived from sorbic acid, the stearate derived from stearic acid, the succinate derived from succinic acid, the tartrate derived from tartaric acid, the toluene-p-sulphonate derived from p-toluene sulphonic acid, and the like. Such salts may be formed by procedures well known and described in the art.
Other acids such as oxalic acid, which may not be considered pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining a chemical compound of the invention and its pharmaceutically acceptable acid addition salt.
Metal salts of a chemical compound of the invention include alkali metal salts such as the sodium salt of a chemical compound of the invention containing a carboxy group.
In the context of this invention the "onium salts" of N-containing compounds are also contemplated as pharmaceutically acceptable salts. Preferred "onium salts" include the alkyl-onium salts, the cycloalkyl-onium salts, and the cycloalkylalkyl-onium salts.
Steric Isomers The chemical compounds of the present invention may exist in (+) and (-) forms as well as in racemic forms (±). The racemates of these isomers and the individual isomers themselves are within the scope of the present invention.
Racemic forms can be resolved into the optical antipodes by known methods and techniques. One way of separating the diastereomeric salts is by use of an optically active acid, and liberating the optically active amine compound by treatment with a base. Another method for resolving racemates into the optical antipodes is based upon chromatography on an optical active matrix. Racemic compounds of the present invention can thus be resolved into their optical antipodes, e.g., by fractional crystallisation of d- or I- (tartrates, mandelates, or camphorsulphonate) salts for example.
The chemical compounds of the present invention may also be resolved by the formation of diastereomeric amides by reaction of the chemical compounds of the present invention with an optically active activated carboxylic acid such as that derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) camphanic acid or by the formation of diastereomeric carbamates by reaction of the chemical compound of the present invention with an optically active chloroformate or the like.
Additional methods for the resolving the optical isomers are known in the art. Such methods include those described by Jaques J, Collet A, & Wilen S in "Fnantiomers. Racemates. and Resolutions", John Wiley and Sons, New York (1981 ). Optical active compounds can also be prepared from optical active starting materials.
Methods of Preparation The chemical substances of the invention may be prepared by conventional methods for chemical synthesis, e.g. those described in the working examples. The starting materials for the processes described in the present application are known or may readily be prepared by conventional methods from commercially available chemicals. Also one compound of the invention can be converted to another compound of the invention using conventional methods.
The end products of the reactions described herein may be isolated by conventional techniques, e.g. by extraction, crystallisation, distillation, chromatography, etc.
Biological Activity
The present invention relates to novel chemical substances, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors (nAChR), and modulators of the monoamine receptors, in particular the biogenic amine transporters 5-HT, DA and NE. Also preferred compounds of the invention show selective α7 activity.
In the context of this invention the term "modulator" covers agonists, partial agonists, antagonists and allosteric modulators of the receptor.
Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or conditions as diverse as CNS related diseases, PNS related diseases, diseases related to smooth muscle contraction, endocrine disorders, diseases related to neuro-degeneration, diseases related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. In a preferred embodiment the compounds of the invention are used for the treatment of diseases, disorders, or conditions relating to the central nervous system. Such diseases or disorders includes anxiety, cognitive disorders, learning deficit, memory deficits and dysfunction, Alzheimer's disease, attention deficit, attention deficit hyperactivity disorder, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Gilles de la Tourette's syndrome, depression, mania, manic depression, schizophrenia, obsessive compulsive disorders (OCD), panic disorders, eating disorders such as anorexia nervosa, bulimia and obesity, narcolepsy, nociception, AIDS-dementia, senile dementia, periferic neuropathy, autism, dyslexia, tardive dyskinesia, hyperkinesia, epilepsy, bulimia, post-traumatic syndrome, social phobia, sleeping disorders, pseudodementia, Ganser's syndrome, pre-menstrual syndrome, late luteal phase syndrome, chronic fatigue syndrome, mutism, trichotillomania, and jet-lag.
In another preferred embodiment the compounds of the invention may be useful for the treatment of diseases, disorders, or conditions associated with smooth muscle contractions, including convulsive disorders, angina pectoris, premature labour, convulsions, diarrhoea, asthma, epilepsy, tardive dyskinesia, hyperkinesia, premature ejaculation, and erectile difficulty.
In yet another preferred embodiment the compounds of the invention may be useful for the treatment of endocrine disorders, such as thyrotoxicosis, pheochromocytoma, hypertension and arrhythmias.
In still another preferred embodiment the compounds of the invention may be useful for the treatment of neurodegenerative disorders, including transient anoxia and induced neuro-degeneration. In even another preferred embodiment the compounds of the invention may be useful for the treatment of inflammatory diseases, disorders, or conditions, including inflammatory skin disorders such as acne and rosacea, Chron's disease, inflammatory bowel disease, ulcerative colitis, and diarrhoea.
In still another preferred embodiment the compounds of the invention may be useful for the treatment of mild, moderate or even severe pain of acute, chronic or recurrent character, as well as pain caused by migraine, postoperative pain, and phantom limb pain.
Finally the compounds of the invention may be useful for the treatment of withdrawal symptoms caused by termination of use of addictive substances. Such addictive substances include nicotine containing products such as tobacco, opioids such as heroin, cocaine and morphine, benzodiazepines and benzodiazepine-like drugs, and alcohol. Withdrawal from addictive substances is in general a traumatic experience characterised by anxiety and frustration, anger, anxiety, difficulties in concentrating, restlessness, decreased heart rate and increased appetite and weight gain.
In this context "treatment" covers treatment, prevention, prophylactics and alleviation of withdrawal symptoms and abstinence as well as treatment resulting in a voluntary diminished intake of the addictive substance.
In another aspect, the compounds of the invention are used as diagnostic agents, e.g. for the identification and localisation of nicotinic receptors in various tissues. Neuroimaging
The chemical substances of the invention may be useful as diagnostic tools or monitoring agents in various diagnostic methods, and in particular for in vivo receptor imaging (neuroimaging). 5 In another aspect of the invention, a method for the non-invasive determination of the distribution of a tracer compound inside a whole, intact living animal or human body using a physical detection method is provided. According to this method a tracer compound is a compound of the invention, or any of its enantiomers or any mixture thereof, an N oxide thereof, a pharmaceutically 10 acceptable salt thereof, in a labelled or un-labelled form.
In a preferred embodiment the physical detection method is selected from PET, SPECT; MRS, MRI, CAT, or combinations thereof.
The labelled compound of the invention preferably contains at least one radionuclide as a label. Positron emitting radionuclides are all candidates for usage. In 15 the context of this invention the radionuclide is preferably selected from 2H (deuterium), 3H (tritium), 11C, 13C, 14C, 150, 13N, 123l, 125l, 131l, 18F and 99m Tc.
An example of commercially available labelling agents, which can be used in the preparation of the labelled compounds of the present invention is [11C]02, 18F, and Nal with different isotopes of Iodine. 20 In particular [11C]02 may be converted to a [11C]-methylating agent, such as [11C]H3I or [11C]-methyl triflate.
The tracer compound can be selected in accordance with the detection method chosen.
In one preferred embodiment, the labelled or unlabelled compound of the 25 invention can be detected by a suitable spectroscopic method, in particular UV spectroscopy and/or fluorescence spectroscopy.
In anther preferred embodiment, the compounds of the invention labelled by incorporation of a isotope into the molecule, which may in particular be an isotope of the naturally occurring atoms including 2H (deuterium), 3H (tritium), 11C, 13C, 14C,
30 150, 13N, 23l, 125l, 131l, 18F and 99m Tc, and the isotope incorporation may be measured by conventional scintillation counting techniques.
In a third preferred embodiment, the physical method for detecting said tracer compound of the present invention is selected from Position Emission
Tomography (PET), Single Photon Imaging Computed Tomography (SPECT),
35 Magnetic Resonance Spectroscopy (MRS), Magnetic Resonance Imaging (MRI), and
Computed Axial X-ray Tomography (CAT), or combinations thereof.
Before conducting the method of the present invention, a diagnostically effective amount of a labelled or unlabelled compound of the invention is administered to a living body, including a human. The compounds of the invention is believed to be particularly suited for in vivo receptor imaging (neuroimaging).
In a particularly preferred embodiment the physical method for detecting the compound of the invention is Position Emission Tomography (PET). It is currently believed that the diagnostically effective amount of the labelled or unlabelled compound of the invention, to be administered before conducting the in vivo method for the invention, is within a range of from 0.1 ng to 100 mg per kg body weight, preferably within a range of from 1 ng to 10 mg per kg body weight.
Pharmaceutical Compositions
In another aspect the invention provides novel pharmaceutical compositions comprising a therapeutically effective amount of the chemical substance of the invention. While a chemical compound of the invention for use in therapy may be administered in the form of the raw chemical compound, it is preferred to introduce the active ingredient, optionally in the form of a physiologically acceptable salt, in a pharmaceutical composition together with one or more adjuvants, excipients, carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries. In a preferred embodiment, the invention provides pharmaceutical compositions comprising the chemical substance of the invention, or a pharmaceutically acceptable salt or derivative thereof, together with one or more pharmaceutically acceptable carriers therefore, and, optionally, other therapeutic and/or prophylactic ingredients, know and used in the art. The carriers) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the recipient thereof.
The pharmaceutical composition of the invention may be administered by any convenient route, which suits the desired therapy. Preferred routes of administration include oral administration, in particular in tablet, in capsule, in drage, in powder, or in liquid form, and parenteral administration, in particular cutaneous, subcutaneous, intramuscular, or intravenous injection. The pharmaceutical composition of the invention can be manufactured by any skilled person by use of standard methods and conventional techniques appropriate to the desired formulation. When desired, compositions adapted to give sustained release of the active ingredient may be employed.
Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA). The actual dosage depend on the nature and severity of the disease being treated, and is within the discretion of the physician, and may be varied by titration of the dosage to the particular circumstances of this invention to produce the desired therapeutic effect. However, it is presently contemplated that pharmaceutical compositions containing of from about 0.1 to about 500 mg of active ingredient per individual dose, preferably of from about 1 to about 100 mg, most preferred of from about 1 to about 10 mg, are suitable for therapeutic treatments.
The active ingredient may be administered in one or several doses per day.
A satisfactory result can, in certain instances, be obtained at a dosage as low as 0.1 μg/kg i.v. and 1 μg/kg p.o. The upper limit of the dosage range is presently considered to be about 10 mg/kg i.v. and 100 mg/kg p.o. Preferred ranges are from about 0.1 μg/kg to about 10 mg/kg/day i.v., and from about 1 μg/kg to about 100 mg/kg/day p.o.
Methods of Therapy The chemical substances of the present invention are valuable nicotinic and monoamine receptor modulators, and therefore useful for the treatment of a range of ailments involving cholinergic dysfunction as well as a range of disorders responsive to the action of nAChR modulators.
In another aspect the invention provides a method for the treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disease, disorder or condition is responsive to modulation of cholinergic receptors and/or monoamine receptors, and which method comprises administering to such a living animal body, including a human, in need thereof an effective amount of a compound of the invention. In a preferred embodiment, the disease, disorder or condition relates to the central nervous system.
In a preferred embodiment, the disease, disorder or condition is anxiety, cognitive disorders, learning deficit, memory deficits and dysfunction, Alzheimer's disease, attention deficit, attention deficit hyperactivity disorder, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Gilles de la Tourette's syndrome, depression, mania, manic depression, schizophrenia, obsessive compulsive disorders (OCD), panic disorders, eating disorders such as anorexia nervosa, bulimia and obesity, narcolepsy, nociception, AIDS-dementia, senile dementia, periferic neuropathy, autism, dyslexia, tardive dyskinesia, hyperkinesia, epilepsy, bulimia, post-traumatic syndrome, social phobia, sleeping disorders, pseudodementia, Ganser's syndrome, pre-menstrual syndrome, late luteal phase syndrome, chronic fatigue syndrome, mutism, trichotillomania, and jet-lag.
In a another preferred embodiment, the disease, disorder or condition are associated with smooth muscle contractions, including convulsive disorders, angina pectoris, premature labour, convulsions, diarrhoea, asthma, epilepsy, tardive dyskinesia, hyperkinesia, premature ejaculation, and erectile difficulty.
In a third preferred embodiment, the disease, disorder or condition is related to the endocrine system, such as thyrotoxicosis, pheochromocytoma, hypertension and arrhythmias.
In a fourth preferred embodiment, the disease, disorder or condition is a neurodegenerative disorders, including transient anoxia and induced neuro- degeneration.
In a fifth preferred embodiment, the disease, disorder or condition is an inflammatory disorder, including inflammatory skin disorders such as acne and rosacea, Chron's disease, inflammatory bowel disease, ulcerative colitis, and diarrhoea.
In a sixth preferred embodiment, the disease, disorder or condition is mild, moderate or even severe pain of acute, chronic or recurrent character, as well as pain caused by migraine, postoperative pain, and phantom limb pain.
In a seventh preferred embodiment, the disease, disorder or condition is associated with withdrawal symptoms caused by termination of use of addictive substances, including nicotine containing products such as tobacco, opioids such as heroin, cocaine and morphine, benzodiazepines and benzodiazepine-like drugs, and alcohol.
It is at present contemplated that suitable dosage ranges are 0.1 to 1000 milligrams daily, 10-500 milligrams daily, and especially 30-100 milligrams daily, dependent as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge.
A satisfactory result can, in certain instances, be obtained at a dosage as low as 0.005 mg/kg i.v. and 0.01 mg/kg p.o. The upper limit of the dosage range is about 10 mg/kg i.v. and 100 mg/kg p.o. Preferred ranges are from about 0.001 to about 1 mg/kg i.v. and from about 0.1 to about 10 mg/kg p.o.
EXAMPLES
The invention is further illustrated with reference to the following examples, which are not intended to be in any way limiting to the scope of the invention as claimed. Example 1 Preparatory Example
All reactions involving air sensitive reagents or intermediates were performed under nitrogen and in anhydrous solvents. Magnesium sulfate was used as drying agent in the workup-procedures and solvents were evaporated under reduced pressure.
(±V3-(2-Benzorb1thiθDhenvh-8-methyl-8-azabicvclor3.2.1 loct-2-ene hydrochloric acid salt To a mixture of benzo[b]thiophene (20.2 g, 151 mmol) and diethyl ether
(200 ml), butyllithium in hexane (2.5 M, 66 ml, 166 mmol) was added at room temperature. The mixture was stirred at reflux temperature for 1 hour and then cooled to -70°C. Tropinone (21.4 g, 154 mmol) solved in diethyl ether (150 ml) was added at -70°C and stirred for 1 hour. The reaction mixture was allowed to warm to room temperature overnight. Aqueous sodium hydroxide (200 ml, 1 M) was added, and endo and exo-3-(2-benzo[b]thiophenyl)-3-hydroxy-8-methyl-8-azabicyclo[3.2.1 joctane was isolated by filtration. Yield 46.8 g, 96%.
A mixture of endo and exo-3-(2-benzofuryl)-3-hydroxy-8-methyl-8- azabicyclo[3.2.1 joctane (46.8 g, 116.6 mmol), hydrochloric acid (500 ml, 25%) was stirred at reflux for 5 hours. The solvent was evaporated. Yield 100%. Mp 298°C.
(±V3-(2-Benzo|'b]thiophenylV8-H-8-azabicyclo[3.2.11oct-2-ene hydrochloric acid salt
A mixture of (±)-3-(2-benzothienyl)-8-methyI-8-azabicyclo[3.2.1]oct-2-ene hydrochloric acid (24.4 g, 0.0955 mol), 1-chloroethyl-chloroformate (15.5 ml, 0.143 mol) and xylene (200 ml) was heated and stirred at reflux temperature for 24 hours. Methanol (300 ml) was added followed by stirring and heating at reflux temperature for 22 hours. The mixture was cooled to room-temperature and the product was filtered. The crude product was recrystallised from diethyl ether. Yield 16 g (69 %). Mp
252-259°C.
(+ 3-(2-Benzo[b]thiophenyl)-8-tetf-butoxycarbonyl-8-azabicyclo[3.2.1]oct-2-ene
A mixture of (±)-3-(2-benzo[b]thiophenyl)-8-H-butoxycarbonyl-8- azabicyclo[3.2.1]oct-2-ene (7.72 g, 32 mmol), triethylamine (4.5 ml, 32 mmol), di-ferf- butyl dicarbonate (7.0 g, 32 mmol) and dichloromethane (50 ml) was stirred for 2 hours. The mixture was washed with aqueous sodium hydroxide (50 ml, 1 M). Yield
9.38 g, 86%. (±)-3-(2-Benzo|"blthiophenyl-1 ,1 -dioxide)-8-fer^butoxycarbonyl-8-azabicyclo["3.2.1 loct- 2-ene
A mixture of (±)-3-(2-benzo[b]thiophenyl)-8-ter£-butoxycarbonyl-8- azabicyclo[3.2.1]oct-2-ene (4.5 g, 13.2 mmol), m-chloroperbenzoic acid (10.0 g, 58 mmol) and chloroform (50 ml) was stirred at room temperature for 4 hours. The mixture was filtered and the filtrate was evaporated. Aqueous sodium hydroxide (100 ml, 1 M) was added and the mixture was extracted with diethyl ether (3 x 50 ml). The crude material was purified by chromatography, using a mixture (1 :3) of EtAc and heptane. The title compound was isolated. Yield 3.31 g, 67%.
(±)-3-(2-Benzo|b]thiophenyl-1.1 -dioxide)-8-H-8-azabicyclo 3.2.1 loct-2-ene f umaric acid salt (Compound 1)
A mixture of (±)3-(2-benzo[b]thiophenyl-1 ,1-dioxide)-8-tetf-butoxycarbonyl-
8-azabicyclo[3.2.1]oct-2-ene (2.95 g, 7.9 mmol), trifluoroacetic acid (5.9 ml, 79 mmol) and dichloromethane (50 ml). The mixture was evaporated. Aqueous sodium hydroxide (30 ml, 1 M) was added followed by extraction with ethyl acetate (3 x 30 ml). Chromatography on silica gel with dichloromethane, methanol and cone. ammonia (89:10:1) gave the title compound. Yield 1.52 g, 70%. The corresponding salt was obtained by addition of a diethyl ether and methanol mixture (9:1) saturated with fumaric acid. Mp 261-265°C.
(±)-3-(2-Benzo[b1thiophenyl-1.1 -dioxide)-8-methyl-8-azabicvclo[3.2.1 ]oct-2-ene fumaric acid salt (Compound 2)
A mixture of (±)3-(2-benzo[b]thiophenyl-1 ,1-dioxide)-8-H-8- azabicyclo[3.2.1]oct-2-ene (0.56 g, 2.05 mmol), formic acid (2.3 ml, 61.5 mmol) and formaldehyde (1.7 ml, 61.5 mmol) was stirred at 100°C over night. The mixture was evaporated. Aqueous sodium hydroxide (30 ml, 1 M) was added followed by extraction with ethyl acetate (3 x 30 ml). Chromatography on silica gel with dichloromethane, methanol and cone, ammonia (89:10:1) gave the title compound. The corresponding salt was obtained by addition of a diethyl ether and methanol mixture (9:1 ) saturated with fumaric acid. Yield 0.42 g, 51%. Mp 198.6-203.4°C.
(+W3-(2-Benzorb1thiophenyl-1.1 -dioxideV8-allyl-8-azabicyclo[3.2.1 ]oct-2-ene (Compound 3) A mixture of (±)3-(2-benzo[b]thiophenyl-1 ,1-dioxide)-8-H-8- azabicyclo[3.2.1]oct-2-ene (0.16 g, 0.58 mmol), 3-bromo-1-propene (54 ul, 0.64 mmol), diisopropylethylamine (102 ul, 0.58 mmol), DMF (10 ml) was stirred at 80°C for 2 days. Aqueous sodium hydroxide (20 ml, 1 M) was added. The mixture was extracted with diethylether (3 x 30 ml). Chromatography on silica gel with dichloromethane, methanol and cone, ammonia (89:10:1) gave the title compound as an oil. Yield: 50 mg (28%).
(+ 3-(2-Benzorb1thiophenyl-1.1-dioxide)-8-ethyl-8-azabicvclor3.2.noct-2-ene (Compound 4)
A mixture of (±)3-(2-benzo[b]thiophenyl-1 ,1-dioxide)-8-H-8- azabicyclo[3.2.1]oct-2-ene (0.18 g, 0.66 mmol), 3-bromoethane (54 ul, 0.72 mmol), diisopropylethylamine (115 ul, 0.66 mmol), DMF (10 ml) was stirred at 80°C for 2 days. Aqueous sodium hydroxide (20 ml, 1 M) was added. The mixture was extracted with diethylether (3 x 30 ml). Chromatography on silica gel with dichloromethane, methanol and cone, ammonia (89:10:1 ) gave the title compound as an oil. Yield: 30 mg (15%).
(±)-3-(2-BenzothiophenylVquinuclidine-2-ene (Intermediate compound) To a mixture of benzothiophene (20.5 g, 154 mmol) in diethyl ether at 20°C was added: butyilithium (67 ml, 2.5 M). The mixture was stirred at room temperature for 30 minutes. 3-Quinuclidinone (19.2 g, 153 mmol) solved in diethylether (200 ml) was added to the mixture at -70°C followed by stirring at the same temperature for 1 hour. The temperature was allowed to reach room temperature. Water (10 ml) was added, followed by aqueous sodium hydroxide (200 ml, 1 M). The mixture was stirred, filtered and washed with diethyl ether (50 ml). Yield (of the alcohol): 33.55 g (84%). A mixture of the alcohol (10.0 g, 38.6 mmol) and hydrochloric acid (100 ml, 25%) was stirred at 70°C for 3 days. The mixture was evaporated. Aqueous sodium hydroxide (125 ml, 1 M) was added, and the mixture was extracted with diethyl ether. Chromatography on silica gel with dichloromethane, methanol and cone, ammonia (89:10:1) gave the title compound. Yield: 8.33 g (88%).
(±)-3-(2-Benzothiophenyl-1.1-dioxide)-quinuclidine-2-ene-N-oxide (Intermediate compound) A mixture of (±)-3-(2-benzothiophenyl)-quinuclidine-2-ene (3.0 g, 12.3 mmol) m-chloroperbenzoic acid (12.76 g, 74 mmol) and 50 ml dichloromethane was stirred for 15 hours. The mixture was filtered, the solid was washed with dichloromethane and the filtrate was purified by chromatography on silica gel with dichloromethane, methanol and cone, ammonia (89:10:1) gave the title compound as a solid. Mp 125-135°C.
(+)-3-(2-Benzothiophenyl-1.1-dioxide quinuclidine-2-ene fumaric acid salt (Compound 5
A mixture of (±)-3-(2-benzothiophenyl-1 ,1-dioxide)-quinuclidine-2-ene-N- oxide (1.35 g, 4.7 mmol), triphenylphosphine (3.67 g, 14.0 mmol) and dioxane (30 ml) was stirred at reflux for 2 hours. The solvent was evaporated, aqueous sodium hydroxide (100 ml, 1 M) was added and the mixture was extracted with dichloromethane (2 x 50 mi). Chromatography on silica gel with dichloromethane, methanol and cone, ammonia (89:10:1) gave the title compound as free base. The corresponding salt was obtained by addition of a diethyl ether and methanol mixture (9:1) saturated with fumaric acid. Mp 233°C.
(±)-3-(2-Benzothiophenyl-1.1-dioxide)-quinuclidine-2-ene-N-methyl iodide salt (Compound 6) A mixture of (±)-3-(2-Benzothiophenyl-1 ,1-dioxide)-quinuclidine-2-ene (100 mg, 0.4 mmol), methyl iodide (75 mg, 0.5 mmol) and 5 ml dichloromethane was stirred at room temperature for 15 hours. The mixture was evaporated. The solid was triturated with diethylether (10 ml). Yield 100 mg (95%). Mp 226.3°C.
Example 2
In vitro Inhibition of 3H-α-Bungarotoxine Binding in Rat Brain
In this example the affinity of the compounds of the invention for binding to α7-subtype of nicotinic receptors is determined. α-Bungarotoxine is a peptide isolated from the venom of the Elapidae snake Bungarus multicinctus. It has high affinity for neuronal and neuromuscular nicotinic receptors, where it acts as a potent antagonist.
3H-α-Bungarotoxine labels nicotinic acetylcholine receptors formed by the α7 subunit isoform found in brain and the α-i isoform in the neuromuscular junction.
Tissue preparation
Preparations are performed at 0-4°C. Cerebral cortices from male Wistar rats (150-250 g) are homogenised for 10 seconds in 15 ml of 20 mM Hepes buffer containing 118 mM NaCI, 4.8 mM KCI, 1.2 mM MgS04 and 2.5 mM CaCI2 (pH 7.5) using an Ultra-Turrax homogeniser. The tissue suspension is subjected to centrifugation at 27,000 x g for 10 minutes. The supernatant is discarded and the pellet is washed twice by centrifugation at 27,000 x g for 10 minutes in 20 ml of fresh buffer, and the final pellet is then re-suspended in fresh buffer containing 0.01 % BSA (35 ml per g of original tissue) and used for binding assays.
Assay
Aliquots of 500 μl of homogenate are added to 25 μl of test solution and 25 μl of 3H- -bungarotoxine (2 nM, final concentration) and mixed and incubated for 2 hours at 37°C. Non-specific binding is determined using (-)-nicotine (1 mM, final concentration). After incubation, the samples are added 5 ml of ice-cold Hepes buffer containing 0.05% PEI and poured directly onto Whatman GF/C glass fibre filters (pre- soaked in 0.1 % PEI for at least 6 hours) under suction, and immediately washed with 2 x 5 ml ice-cold buffer.
The amount of radioactivity on the filters is determined by conventional liquid scintillation counting. Specific binding is total binding minus non-specific binding.
The test value is given as an IC50 (the concentration of the test substance which inhibits the specific binding of 3H-α-bungarotoxin by 50%).
The results of these experiments are presented in Table 1 below.
Table 1
Inhibition of 3H-α-Bunαarotoxine Binding
Figure imgf000026_0001
Example 3
In vitro Inhibition of Η-5-Hydroxytryptamine Uptake in Cortical Synaptosomes
Serotonin transporters/uptake sites on nerve terminals presumably function to terminate neuronal signaling by removing serotonin from the synaptic cleft. The activity of the serotonin transporter integral protein can be measured in vitro by synaptosomal uptake of 3H-5-hydroxytryptamine (5-HT, serotonin).
Preparations are performed at 0-4°C. Cerebral cortices from male Wistar rats (150-200 g) are homogenized for 5-10 seconds in 100 volumes of ice-cold 0.32 M sucrose containing 1 mM pargyline, using a motor driven teflon pestle in a glass homogenizing vessel. Monoamine oxidase activity is inhibited in the presence of pargyline.
The homogenate is subjected to centrifugation at 1000 x g for 10 minutes. The resulting supernatant is then centrifuged at 27,000 x g for 50 minutes and the supernatant is discarded. The pellet (P2) is re-suspended in oxygenated (equilibrated with an atmosphere of 96% 02: 4% C02 for at least 30 minutes) Krebs-Ringer incubation buffer (1000 ml per g of original tissue) at pH 7.2 containing 122 mM NaCI, 0.16 mM EDTA, 4.8 mM KCI, 12.7 mM Na2HP04, 3.0 mM NaH2P04, 1.2 mM MgS04, 1 mM CaCI2, 10 mM glucose and 1 mM ascorbic acid.
Aliquots of 4.0 ml tissue suspension are added to 100 μl of test solution and 100 μl of Η-5-HT (1 nM, final concentration), mixed and incubated for 30 minutes at 37°C. Non-specific uptake is determined using Citalopram (1 μM, final concentration, available from Lundbeck, Denmark).
After incubation, the samples are poured directly onto Whatman GF/C glass fibre filters under suction. The filters are washed three times with 5 ml of ice- cold 0.9% (w/v) NaCI solution.
The amount of radioactivity on the filters is determined by conventional liquid scintillation counting. Specific uptake is calculated as the difference between total uptake and non-specific uptake.
25-75% inhibition of specific binding must be obtained, before calculation of an IC50.
The test value is given as IC50 (the concentration (μM) of the test substance which inhibits the specific binding of 3H-5-HT by 50%).
The results are presented in Table 2 below.
Table 2
Inhibition of 3H-5-Hydroxytrvptamine Uptake
Figure imgf000027_0001

Claims

1. A chemical substance represented by the general Formula I
Figure imgf000028_0001
any of its enantiomers or any mixture of enantiomers, or a pharmaceutically- acceptable addition salt thereof, wherein
A, B, D, E and G, independently of each another, represent a carbon (C) or a nitrogen (N) atom, constituting an aromatic ring system; and
X represents a group of Formula II
Figure imgf000028_0002
R a group of Formula III
Figure imgf000028_0003
a group of Formula IV
Figure imgf000028_0004
a group of Formula V
Figure imgf000028_0005
a group of Formula VI
Figure imgf000028_0006
a group of Formula VII
Figure imgf000029_0001
or a group of Formula VIII
Figure imgf000029_0002
in which formulas
— represents a single or a double bond (an optionally double bond); n is 0, 1 , 2 or 3; m is 1 , 2 or 3; and
R represents hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl.
The chemical substance of claim 1 , which substance is a benzo[b]thiophene derivative of Formula IA
Figure imgf000029_0003
a benzo[b]thiazole derivative of Formula IB
Figure imgf000029_0004
a thienopyridine derivative of Formula IC
Figure imgf000029_0005
a thienopyridine derivative of Formula ID
Figure imgf000029_0006
a thienopyridine derivative of Formula IE
Figure imgf000030_0001
or a thienopyridine derivative of Formula IF
Figure imgf000030_0002
in which formulas
A and X are as defined in claim 1.
The chemical substance of claim 1 , which is a benzo[b]thiophene derivative of
Formula IA, wherein
X represents a group of Formula II, wherein n is O, 1 or 2; m is 1 , 2 or 3; and
R represents hydrogen, alkyl, or aralkyl.
imidazolidine; 3-methyl-imidazolidine;
1.3-diazacyclohexane;
3-methyl-1.3-diazacyclohexane; piperazine;
4-methyl-piperazine;
4-ethyl-piperazine;
•4-benzyl-piperazine; homopiperazine; 4-methyl-homopiperazine; 4-ethyl-homopiperazine;
4-benzyl-homopiperazine; 1 ,4-diazacyclooctane; 4-methyl-1 ,4-diazacyclooctane;
4-ethyl-1 ,4-diazacyclooctane; 4-benzyl-1 ,4-diazacyclooctane;
1 ,5-diazacyclooctane; 5-methyl-1 ,5-diazacyclooctane;
Figure imgf000030_0003
5-ethyl-1 ,5-diazacyclooctane; or (±) 1-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-5-benzyl-1 ,5-diazacyclooctane; or a pharmaceutically-acceptable addition salt thereof.
5. The chemical substance of claim 1 , which is a benzo[b]thiazole derivative of Formula IB, wherein
X represents a group of Formula II, wherein n is 0, 1 or 2; m is 1 , 2 or 3; and
R represents hydrogen, alkyl, or aralkyl.
6. The chemical substance of claim 5, which is
(±) 1- (2-Benzo[b]thiazolyl-1 , 1-dioxide)-imidazolidine;
(±) 1- (2-Benzo[b]thiazolyl-1 , 1-dioxide)-3-methyl-imidazolidine;
(±) 1- (2-Benzo[b]thiazolyl-1 , 1 -dioxide)-1.3-diazacyclohexane;
(±) 1- (2-Benzo[b]thiazolyl-1 , 1 -dioxide)-3-methyl-1.3-diazacyclohexane;
(+) 1- (2-Benzo[b]thiazolyl-1 , 1 -dioxide)-piperazine;
(±) 1- (2-Benzo[b]thiazolyl-1 , 1-dioxide)-4-methyl-piperazine;
(±) 1- (2-Benzo[b]thiazolyl-1 , 1 -dioxide)-4-ethyl-piperazine;
(±) 1- (2-Benzo[b]thiazolyl-1 , 1-dioxide)-4-benzyl-piperazine;
(±) 1- (2-Benzo[b]thiazolyl-1 , 1 -dioxide)-homopiperazine;
(±) 1- (2-Benzo[b]thiazolyl-1 , 1-dioxide)-4-methyl-homopiperazine;
(±) 1- (2-Benzo[b]thiazoIyl-1 , 1-dioxide)-4-ethyl-homopiperazine;
(±) 1- (2-Benzo[b]thiazolyl-1 , 1-dioxide)-4-benzyl-homopiperazine;
(±) 1- (2-Benzo[b]thiazolyl-1 , 1 -dioxide)-1 ,4-diazacyclooctane;
(±) 1- (2-Benzo[b]thiazolyl-1 , 1 -dioxide)-4-methyI-1 ,4-diazacyclooctane;
(±) 1- (2-Benzo[b]thiazolyl-1 , 1 -dioxide)-4-ethyI-1 ,4-diazacyclooctane;
(±) 1- (2-Benzo[b]thiazolyl-1 , 1 -dioxide)-4-benzyl-1 ,4-diazacyclooctane;
(±) 1- ■(2-Benzo[b]thiazolyl-1 , 1-dioxide)-1 ,5-diazacyclooctane;
(±) 1- ■(2-Benzo[b]thiazolyl-1 , 1-dioxide)-5-methyl-1 ,5-diazacyclooctane;
(±) 1- (2-Benzo[b]thiazolyl-1 , 1-dioxide)-5-ethyl-1 ,5-diazacyclooctane; or
(±) 1- (2-Benzo[b]thiazoIyI-1 , 1 -dioxide)-5-benzyl-1 ,5-diazacyclooctane; or a pharmaceutically-accep able addition salt thereof.
7. The chemical substance of claim 1 , which is a benzo[b]thiophene derivative of Formula IA, wherein
X represents a group of Formula III, wherein r z represents a double bond; n is O or 1 ; and
R represents hydrogen, alkyl or aralkyl.
8. The chemical substance of claim 7, which is (±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-8 ■H-8-azabicyclo[3.2.1]oct-2-ene; (±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-8 -methyl-8-azabicyclo[3.2.1 ]oct-2-ene; (±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-8 ■ethyl-8-azabicyclo[3.2.1]oct-2-ene; (±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-8 ■allyl-8-azabicyclo[3.2.1]oct-2-ene; (±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-8 ■benzyl-8-azabicyclo[3.2.1 ]oct-2-ene; (±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-9 ■H-9-azabicyclo[3.3.1 ]non-2-ene; (±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-9 -methyl-9-azabicyclo[3.3.1 ]non-2-ene; (±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-9 ■ethyl-9-azabicyclo[3.3.1]non-2-ene; (±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-9 ■benzyl-9-azabicyclo[3.3.1 ]non-2-ene; or a pharmaceutically-acceptable addition salt thereof.
9. The chemical substance of claim 1 , which is a benzo[b]thiazole derivative of Formula IB, wherein
X represents a group of Formula III, wherein
— represents a double bond; n is 0 or 1 ; and
R represents hydrogen, alkyl or aralkyl.
10. The chemical substance of claim 9, which is ±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-8-H-8-azabicyclo[3.2.1]oct-2-ene;
±) 3-(2-Benzo[b]thiazolyl-1 1-dioxide)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene; ±) 3-(2-Benzo[b]thiazolyl-1 1-dioxide)-8-ethyl-8-azabicyclo[3.2.1]oct-2-ene; +) 3-(2-Benzo[b]thiazolyl-1 1-dioxide)-8-benzyl-8-azabicyclo[3.2.1]oct-2-ene; ±) 3-(2-Benzo[b]thiazolyl-1 1-dioxide)-9-H-9-azabicyclo[3.3.1]non-2-ene; ±) 3-(2-Benzo[b]thiazolyl-1 1-dioxide)-9-methyl-9-azabicyclo[3.3.1]non-2-ene; ±) 3-(2-Benzo[b]thiazolyl-1 1-dioxide)-9-ethyl-9-azabicyclo[3.3.1]non-2-ene; or ±) 3-(2-Benzo[b]thiazolyl-1 1-dioxide)-9-benzyl-9-azabicyclo[3.3.1]non-2-ene; or a pharmaceutically-acceptable addition salt thereof.
11. The chemical substance of claim 1 , which is a benzo[b]thiophene derivative of Formula IA, wherein
X represents a group of Formula IV, wherein — represents a double bond; n is 0 or 1 ; and R represents hydrogen or alkyl.
12. The chemical substance of claim 11 , which is (±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-7-H-7-azabicyclo[3.3.0]oct-2-ene; (±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-7-methyl-7-azabicyclo[3.3.0]oct-2-ene; (±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-7-ethyl-7-azabicyclo[3.3.0]oct-2-ene; or (±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-7-benzyl-7-azabicyclo[3.3.0]oct-2-ene; or a pharmaceutically-acceptable addition salt thereof.
13. The chemical substance of claim 1 , which is a benzo[b]thiazole derivative of Formula IB, wherein
X represents a group of Formula IV, wherein ;== represents a double bond; n is 0 or 1 ; and R represents hydrogen or alkyl.
14. The chemical substance of claim 13, which is (±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-7-H-7-azabicyclo[3.3.0]oct-2-ene;
(±) 3-(2-Benzo[b]thiazolyl-1,1-dioxide)-7-methyl-7-azabicyclo[3.3.0]oct-2-ene; (±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-7-ethyl-7-azabicyclo[3.3.0]oct-2-ene; or (±) 3-(2-Benzo[b]thiazolyl-1 , 1 -dioxide)-7-benzyl-7-azabicyclo[3.3.0]oct-2-ene; or a pharmaceutically-acceptable addition salt thereof.
, 15. The chemical substance of claim 1 , which is a benzo[b]thiophene derivative of Formula IA, wherein
X represents a group of Formula V, wherein n is 0, 1 or 2; m is 1 or 2; and
R represents hydrogen or alkyl.
16. The chemical substance of claim 15, which is
(±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-9-H-3,9-diazabicyclo-[4.2.1]-nonane; (+) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-9-methyl-3,9-diazabicyclo-[4.2.1]- nonane;
(±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-9-ethyl-3,9-diazabicyclo-[4.2.1]-nonane;
(±) 3-(2-Benzo[b]thiophenyl-1 , 1 -dioxide)-10-H-3, 10-diazabicyclo-[4.3.1 ]-decane;
(±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-10-methyl-3,10-diazabicyclo-[4.3.1]- decane;
(±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-10-ethyl-3,10-diazabicyclo-[4.3.1]- decane; or a pharmaceutically-acceptable addition salt thereof.
17. The chemical substance of claim 1 , which is a benzo[b]thiazole derivative of Formula IB, wherein
X represents a group of Formula V, wherein n is 0, 1 or 2; m is 1 or 2; and
R represents hydrogen or alkyl.
18. The chemical substance of claim 17, which is (±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-9-H-3,9-diazabicyclo-[4.2.1]-nonane; (+) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-9-methyl-3,9-diazabicyclo-[4.2.1]-nonane;
(±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-9-ethyl-3,9-diazabicyclo-[4.2.1]-nonane;
(±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-10-H-3,10-diazabicyclo-[4.3.1]-decane;
(±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-10-methyl-3,10-diazabicyclo-[4.3.1j- decane; or (±) 3-(2-Benzo[b]thiazolyl-1 , 1 -dioxide)-10-ethyl-3, 10-diazabicyclo-[4.3.1 ]-decane; or a pharmaceutically-acceptable addition salt thereof.
19. The chemical substance of claim 1 , which is a benzo[b]thiophene derivative of Formula IA, wherein X represents a group of Formula VI, wherein n is O or 1 ; and R represents hydrogen, alkyl, phenyl or benzyl.
20. The chemical substance of claim 19, which is (±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-7-H-3,7-diazabicyclo[3.3.0]octane;
(±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-7-methyl-3,7-diazabicyclo[3.3.0]octane;
(±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-7-phenyl-3,7-diazabicyclo[3.3.0]octane;
(±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-7-benzyl-3,7-diazabicyclo[3.3.0]octane;
(±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-7-H-3,7-diazabicyclo[3.3.1]nonane; (±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-7-methyl-3,7- diazabicyclo[3.3.1]nonane;
(±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-7-phenyl-3,7- diazabicyclo[3.3.1]nonane;
(±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-7-benzyl-3,7-diazabicyclo[3.3.1 ]nonane; or a pharmaceutically-acceptable addition salt thereof.
21. The chemical substance of claim 1 , which is a benzo[b]thiazole derivative of Formula IB, wherein
X represents a group of Formula VI, wherein n is 0 or 1 ; and
R represents hydrogen, alkyl, phenyl or benzyl.
22. The chemical substance of claim 21 , which is (±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-7-H-3,7-diazabicyclo[3.3.0]octane;
(±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-7-methyl-3,7-diazabicyclo[3.3.0]octane;
(±) 3-(2-Benzo[b]thiazolyl-1 , 1 -dioxide)-7-phenyl-3,7-diazabicyclo[3.3.0]octane;
(±) 3-(2-Benzo[b]thiazolyl-1,1-dioxide)-7-benzyl-3,7-diazabicyclo[3.3.0]octane;
(±) 3-(2-Benzo[b]thiazolyl-1,1-dioxide)-7-H-3,7-diazabicyclo[3.3.1]nonane; (±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-7-methyl-3,7-diazabicyclo[3.3.1]nonane;
(±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-7-phenyl-3,7-diazabicyclo[3.3.1]nonane; or
(±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-7-benzyl-3,7-diazabicyclo[3.3.1]nonane; or a pharmaceutically-acceptable addition salt thereof.
23. The chemical substance of claim 1 , which is a benzo[b]thiophene derivative of Formula IA, wherein
X represents a group of Formula VII, wherein R represents hydrogen or alkyl.
24. The chemical substance of claim 23, which is (±) 2-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-(1 S,4S)-(+)-5-H-2,5-diazabicyclo-[2.2.1]- heptane; (±) 2-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-(1 S,4S)-(+)-5-methyl-2,5-diazabicyc)o- [2.2.1]-heptane; or a pharmaceutically-acceptable addition salt thereof.
25. The chemical substance of claim 1 , which is a benzo[b]thiazole derivative of Formula IB, wherein X represents a group of Formula VII, wherein
R represents hydrogen or alkyl.
26. The chemical substance of claim 25, which is (±) 2-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-(1S,4S)-(+)-5-H-2,5-diazabicyclo-[2.2.1]- heptane; or
(±) 2-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-(1 S,4S)-(+)-5-methyl-2,5-diazabicyclo-
[2.2.1]-heptane; or a pharmaceutically-acceptable addition salt thereof.
27. The chemical substance of claim 1 , which is a benzo[b]thiophene derivative of Formula IA, wherein
X represents a group of Formula VIII, wherein — represents a single bond or a double bond.
28. The chemical substance of claim 27, which is (±) 3-(2-Benzo[b]thiophenyl-1,1-dioxide)-quinuclidine;
(±) 3-(2-Benzo[b]thiophenyl-1 ,1-dioxide)-quinuclidine-2-ene; or (±)-3-(2-Benzothiophenyl-1 ,1-dioxide)-quinuclidine-2-ene-N-methyl; or a pharmaceutically-acceptable addition salt thereof.
29. The chemical substance of claim 1 , which is a benzo[b]thiazole derivative of Formula IB, wherein
X represents a group of Formula VIII, wherein r represents a single bond or a double bond.
30. The chemical substance of claim 29, which is
(±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-quinuclidine; or (±) 3-(2-Benzo[b]thiazolyl-1 ,1-dioxide)-quinuclidine-2-ene; or a pharmaceutically-acceptable addition salt thereof.
31. A pharmaceutical composition comprising a therapeutically effective amount of a chemical substance of any of claims 1-30, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, together with at least one pharmaceutically-acceptable carrier or diluent.
32. Use of a chemical substance of any of claims 1-30, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, for the treatment, prevention or alleviation of a disease or a disorder or a condition which is responsive to modulation of cholinergic receptors and/or monoamine receptors.
33. The use according to claim 32, wherein the disease, disorder or condition relates to the central nervous system.
34. The use according to claim 33, wherein the disease, disorder or condition is anxiety, cognitive disorders, learning deficit, memory deficits and dysfunction, Alzheimer's disease, attention deficit, attention deficit hyperactivity disorder, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Gilles de la Tourette's syndrome, depression, mania, manic depression, schizophrenia, obsessive compulsive disorders (OCD), panic disorders, eating disorders such as anorexia nervosa, bulimia and obesity, narcolepsy, nociception, AIDS- dementia, senile dementia, periferic neuropathy, autism, dyslexia, tardive 5 dyskinesia, hyperkinesia, epilepsy, bulimia, post-traumatic syndrome, social phobia, sleeping disorders, pseudodementia, Ganser's syndrome, pre-menstrual syndrome, late luteal phase syndrome, chronic fatigue syndrome, mutism, trichotillomania, and jet-lag.
10 35. The use according to claim 32, wherein the disease, disorder or condition are associated with smooth muscle contractions, including convulsive disorders, angina pectoris, premature labour, convulsions, diarrhoea, asthma, epilepsy, tardive dyskinesia, hyperkinesia, premature ejaculation, and erectile difficulty.
15 36. The use according to claim 32, wherein the disease, disorder or condition is related to the endocrine system, such as thyrotoxicosis, pheochromocytoma, hypertension and arrhythmias.
37. The use according to claim 32, wherein the disease, disorder or condition is a 20 neurodegenerative disorders, including transient anoxia and induced neuro- degeneration.
38. The use according to claim 32, wherein the disease, disorder or condition is an inflammatory disorder, including inflammatory skin disorders such as acne and
25 rosacea, Chron's disease, inflammatory bowel disease, ulcerative colitis, and diarrhoea.
39. The use according to claim 32, wherein the disease, disorder or condition is mild, moderate or even severe pain of acute, chronic or recurrent character, as
30 well as pain caused by migraine, postoperative pain, and phantom limb pain.
40. The use according to claim 32, wherein the disease, disorder or condition is associated with withdrawal symptoms caused by termination of use of addictive substances, including nicotine containing products such as tobacco, opioids
35 such as heroin, cocaine and morphine, benzodiazepines and benzodiazepine- like drugs, and alcohol.
41. A method of the treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disease or disorder is responsive to modulation of cholinergic receptors and/or monoamine receptors, which method comprises the step of administering to such a living animal body, including a human, in need thereof a therapeutically effective amount of a chemical substance of any of claims 1-30, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof.
PCT/DK2002/000460 2001-07-06 2002-07-02 Novel compounds, their preparation and use WO2003004493A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP02754549A EP1406900B1 (en) 2001-07-06 2002-07-02 Novel compounds, their preparation and use
AU2002320958A AU2002320958B2 (en) 2001-07-06 2002-07-02 Novel compounds, their preparation and use
CA002448913A CA2448913A1 (en) 2001-07-06 2002-07-02 Sulfone containing bicyclic aromatic ring compounds, their preparation and use as nicotinic acetyl-chloine receptors
JP2003510660A JP2004532899A (en) 2001-07-06 2002-07-02 Novel compounds, their production and their use
NZ529880A NZ529880A (en) 2001-07-06 2002-07-02 Novel compounds, their preparation and use
DK02754549T DK1406900T3 (en) 2001-07-06 2002-07-02 New compounds, preparation and use thereof
DE60215172T DE60215172T2 (en) 2001-07-06 2002-07-02 NEW COMPOUNDS, THEIR PREPARATION AND USE
MXPA04000012A MXPA04000012A (en) 2001-07-06 2002-07-02 Novel compounds, their preparation and use.
US10/482,363 US7314870B2 (en) 2001-07-06 2002-07-02 Compounds, their preparation and use
HK05101039A HK1068628A1 (en) 2001-07-06 2005-02-07 Nicotinic acetyl-choline receptors inhibitor compounds, their preparation and use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101064 2001-07-06
DKPA200101064 2001-07-06

Publications (2)

Publication Number Publication Date
WO2003004493A1 true WO2003004493A1 (en) 2003-01-16
WO2003004493A8 WO2003004493A8 (en) 2003-04-10

Family

ID=8160609

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2002/000460 WO2003004493A1 (en) 2001-07-06 2002-07-02 Novel compounds, their preparation and use

Country Status (13)

Country Link
US (1) US7314870B2 (en)
EP (1) EP1406900B1 (en)
JP (1) JP2004532899A (en)
CN (1) CN1229375C (en)
AT (1) ATE341548T1 (en)
AU (1) AU2002320958B2 (en)
CA (1) CA2448913A1 (en)
DE (1) DE60215172T2 (en)
DK (1) DK1406900T3 (en)
HK (1) HK1068628A1 (en)
MX (1) MXPA04000012A (en)
NZ (1) NZ529880A (en)
WO (1) WO2003004493A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016604A3 (en) * 2002-08-14 2004-04-08 Abbott Lab Azabicyclic compounds are central nervous system active agents
WO2005100351A1 (en) * 2004-04-14 2005-10-27 Astrazeneca Ab NOVEL 2-(1-AZA-BICYCLO[2.2.2]OCT-3-yl)-2,3-DIHYDROISOINDOL-l-ONE/5,6-DIHYDRO-FURO[2,3-c]PYRROL-4ONE DERIVATIVES LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR
WO2006064031A1 (en) * 2004-12-17 2006-06-22 Neurosearch A/S Enantiomers of 3-heteroaryl-8h-8-azabicyclo(3.2.1)oct-2-ene and their use as monoamine neurotransmitter re-uptake inhibitors
JP2006517568A (en) * 2003-02-12 2006-07-27 ニューロサーチ、アクティーゼルスカブ 8-Aza-bicyclo [3.2.1] octane derivatives and methods of using them as monoamine neurotransmitter reuptake inhibitors
WO2006096358A1 (en) * 2005-03-04 2006-09-14 Eli Lilly And Company Azabicycloalkane derivatives useful as nicotinic acetylcholine receptor agonists
US7135484B2 (en) 2002-08-14 2006-11-14 Abbott Laboratories Azabicyclic compounds are central nervous system active agents
WO2007135121A1 (en) 2006-05-23 2007-11-29 Neurosearch A/S Novel 8,10-diaza-bicyclo[4.3.1]decane derivatives and their medical use
US20110263640A1 (en) * 2008-11-18 2011-10-27 Neurosearch A/S 8-azabicyclo[3.2.1]oct-2-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050171079A1 (en) * 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
TWI404532B (en) 2006-11-02 2013-08-11 Targacept Inc Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes
EP2642998B1 (en) 2010-11-24 2020-09-16 The Trustees of Columbia University in the City of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
WO2014151959A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
EP2968303B1 (en) 2013-03-14 2018-07-04 The Trustees of Columbia University in the City of New York Octahydrocyclopentapyrroles, their preparation and use
US10273243B2 (en) 2013-03-14 2019-04-30 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
EP3137168B1 (en) 2014-04-30 2022-01-05 The Trustees of Columbia University in the City of New York Substituted 4-phenylpiperidines, their preparation and use
JP7390401B2 (en) * 2019-05-30 2023-12-01 シャンハイ インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズ Fused ring compounds, their production methods and uses
WO2024153165A1 (en) * 2023-01-18 2024-07-25 苏州旺山旺水生物医药股份有限公司 Salt of antidepressant compound, and preparation method therefor, pharmaceutical composition containing same and use thereof
CN118356426A (en) * 2023-01-18 2024-07-19 苏州旺山旺水生物医药股份有限公司 Pharmaceutical composition containing fused ring compound and preparation method and application thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003433A1 (en) * 1990-08-21 1992-03-05 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
WO1993023395A1 (en) * 1992-05-11 1993-11-25 Kabi Pharmacia Ab Heteroaromatic quinuclidinenes, their use and preparation
WO2000064885A1 (en) * 1999-04-26 2000-11-02 Neurosearch A/S Heteroaryl diazacycloalkanes, their preparation and use
WO2000066586A1 (en) * 1999-05-04 2000-11-09 Neurosearch A/S Heteroaryl diazabicycloalkanes, their preparation and use
WO2001036417A1 (en) * 1999-11-18 2001-05-25 Astrazeneca Ab New use and novel n-azabicyclo-amide derivatives
WO2001092261A1 (en) * 2000-05-31 2001-12-06 Sanofi-Synthelabo 1,4-diazabicyclo[3.2.2]nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation and therapeutic use thereof
WO2002044176A1 (en) * 2000-12-01 2002-06-06 Neurosearch A/S 3-substituted quinuclidines and their use as nicotinic agonists

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003433A1 (en) * 1990-08-21 1992-03-05 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
WO1993023395A1 (en) * 1992-05-11 1993-11-25 Kabi Pharmacia Ab Heteroaromatic quinuclidinenes, their use and preparation
WO2000064885A1 (en) * 1999-04-26 2000-11-02 Neurosearch A/S Heteroaryl diazacycloalkanes, their preparation and use
WO2000066586A1 (en) * 1999-05-04 2000-11-09 Neurosearch A/S Heteroaryl diazabicycloalkanes, their preparation and use
WO2001036417A1 (en) * 1999-11-18 2001-05-25 Astrazeneca Ab New use and novel n-azabicyclo-amide derivatives
WO2001092261A1 (en) * 2000-05-31 2001-12-06 Sanofi-Synthelabo 1,4-diazabicyclo[3.2.2]nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation and therapeutic use thereof
WO2002044176A1 (en) * 2000-12-01 2002-06-06 Neurosearch A/S 3-substituted quinuclidines and their use as nicotinic agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NILSSON B M ET AL: "3-HETEROARYL-SUBSTITUTED QUINUCLIDIN-3-OL AND QUINUCLIDIN-2-ENE DERIVATIVES AS MUSCARINIC ANTAGONISTS. SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIPS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 38, no. 3, 1995, pages 473 - 487, XP002017103, ISSN: 0022-2623 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016604A3 (en) * 2002-08-14 2004-04-08 Abbott Lab Azabicyclic compounds are central nervous system active agents
US7135484B2 (en) 2002-08-14 2006-11-14 Abbott Laboratories Azabicyclic compounds are central nervous system active agents
JP2006517568A (en) * 2003-02-12 2006-07-27 ニューロサーチ、アクティーゼルスカブ 8-Aza-bicyclo [3.2.1] octane derivatives and methods of using them as monoamine neurotransmitter reuptake inhibitors
WO2005100351A1 (en) * 2004-04-14 2005-10-27 Astrazeneca Ab NOVEL 2-(1-AZA-BICYCLO[2.2.2]OCT-3-yl)-2,3-DIHYDROISOINDOL-l-ONE/5,6-DIHYDRO-FURO[2,3-c]PYRROL-4ONE DERIVATIVES LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR
US7566727B2 (en) 2004-04-14 2009-07-28 Astrazeneca Ab 2-(1-aza-bicyclo[2.2.2]oct-3-yl)-2,3-dihydro-isoindole-1-one/5,6-dihydro-furo[2,3-c] pyrrol-4-one derivative ligands for alpha 7 nicotinic acetylcholine receptor
WO2006064031A1 (en) * 2004-12-17 2006-06-22 Neurosearch A/S Enantiomers of 3-heteroaryl-8h-8-azabicyclo(3.2.1)oct-2-ene and their use as monoamine neurotransmitter re-uptake inhibitors
US7781456B2 (en) 2004-12-17 2010-08-24 Neurosearch A/S Enantiomers of 3-heteroaryl-8H-8-azabicyclo(3.2.1)oct-2-ene and their use as monoamine neurotransmitter re-uptake inhibitors
WO2006096358A1 (en) * 2005-03-04 2006-09-14 Eli Lilly And Company Azabicycloalkane derivatives useful as nicotinic acetylcholine receptor agonists
WO2007135121A1 (en) 2006-05-23 2007-11-29 Neurosearch A/S Novel 8,10-diaza-bicyclo[4.3.1]decane derivatives and their medical use
US7910578B2 (en) 2006-05-23 2011-03-22 Neurosearch A/S 8,10-diaza-bicyclo[4.3.1]decane derivatives and their medical use
US20110263640A1 (en) * 2008-11-18 2011-10-27 Neurosearch A/S 8-azabicyclo[3.2.1]oct-2-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US8633218B2 (en) * 2008-11-18 2014-01-21 Aniona Aps 8-azabicyclo[3.2.1]oct-2-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Also Published As

Publication number Publication date
DK1406900T3 (en) 2007-01-29
WO2003004493A8 (en) 2003-04-10
DE60215172T2 (en) 2007-08-30
MXPA04000012A (en) 2004-05-21
US20040180877A1 (en) 2004-09-16
US7314870B2 (en) 2008-01-01
CN1520414A (en) 2004-08-11
EP1406900B1 (en) 2006-10-04
ATE341548T1 (en) 2006-10-15
AU2002320958B2 (en) 2008-02-28
CN1229375C (en) 2005-11-30
JP2004532899A (en) 2004-10-28
NZ529880A (en) 2005-09-30
HK1068628A1 (en) 2005-04-29
CA2448913A1 (en) 2003-01-16
DE60215172D1 (en) 2006-11-16
EP1406900A1 (en) 2004-04-14

Similar Documents

Publication Publication Date Title
EP1863819B1 (en) Diazabicyclic aryl derivatives and their use as chinolinergic ligands at the nicotinic acetylcholine receptors
EP1406900B1 (en) Novel compounds, their preparation and use
US7750011B2 (en) Diazabicyclic aryl derivatives and their medical use
US7300933B2 (en) Diazabicyclic biaryl derivatives
AU2002320958A1 (en) Novel compounds, their preparation and use
US20080132704A1 (en) 3-Substituted quinuclidines and their use
EP1339712A1 (en) 3-substituted quinuclidines and their use as nicotinic agonists
EP1987033B1 (en) Diazabicycloalkane derivatives and their medical use
EP1506205B1 (en) Novel azacyclic ethynyl derivatives
US7662812B2 (en) Diazabicyclic aryl derivatives and their use as chinolinergic ligands at nicotinic acetylcholine receptors
US7855208B2 (en) 3, 9-diazabicyclo(3.3.1)non-3-yl-aryl methanone derivatives as nicotinic acetylcholine receptor agonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: PUBLISHED FIGURE DELETED

WWE Wipo information: entry into national phase

Ref document number: 2002754549

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2448913

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 529880

Country of ref document: NZ

Ref document number: 2002320958

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 028128109

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 10482363

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003510660

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/000012

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 2002754549

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 529880

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 529880

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2002754549

Country of ref document: EP